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1. INTRODUCTION 
The ongoing research on bipolar disorder has highlighted its 
pervasive and debilitating nature, characterized by lifelong 
recurrent episodes and residual intraepisodic symptomatology 
(Keck et al., 2007). The natural history of bipolar disorder 
consists of distinct manic, hypomanic, depressive, and mixed 
mood episodes that can morph immediately from one pole to 
another or are separated by periods of subsyndromal symptoms 
and euthymia (Nierenberg et al., 2010).  
Polarity, frequency, duration, and intensity of mood episodes, as 
well as the presence of psychotic symptoms, are highly 
variable. Effective treatments can decrease the frequency, 
duration, and intensity of mood episodes, but most people with 
bipolar disorder will continue to experience fluctuations in mood, 
as well as significant functional and neurocognitive impairment 
(Torrent et al.,2012; Sole et al., 2012.,  Nierenberg et al., 2010).    
Relapse rates, even in treated patients and after a first lifetime 
episode, range from 40% to 60%, with nearly one-half of the 
patients experiencing a second mood episode within a year of 
recovery (Tohen et al., 2006; Tohen et al., 2003).  
 Inadequate treatment results in increased rates of relapse, 
 
 
whereas multiple episodes may create utter vulnerability to 
subsequent episodes and reduce the response to therapy (Ketter et 
al., 2006), impact patients’ psychosocial functioning (Martinez-
Aran et al., 2007; Angst et al., 2002) and increase morbidity and 
mortality (Suppes et al., 2009).   
Over the last decade, a number of effective maintenance 
treatments for bipolar disorder have been developed with an 
evidence base for second-generation antipsychotics and some 
anticonvulsants (Vieta et al., 2011; Fountoulakis et al., 2012), but 
up to date no attempt was made to develop a way to compare the 
drugs used in maintenance treatments of bipolar disorder 
according to their antidepressive vs. antimanic profile (Popovic et 
al., 2012).  
The main objectives of this dissertation are: 
1. To introduce a metric that would enable to compare the 
efficacy profiles of the drugs used for maintenance treatment of 
bipolar disorder as regards to their potential to prevent depressive 
versus manic episodes (Polarity Index) 
2. To introduce Polarity Index for adjunctive psychotherapies 
in maintenance treatment of bipolar disorder 
3. To apply Polarity Index of pharmacological treatments in 
 
 
maintenance therapy to real-world setting. To perform a 
naturalistic study aiming to ally Polarity Index in order to assess 
eventual differences between predominantly manic and 
predominantly depressed patients, with a special focus on their 
pharmacological treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. BACKGROUND 
2.1. Background to Bipolar Disorder 
2.1.1.  Historic overview   
The first referral to Bipolar Disorder dates back to 3000 BC in 
ancient Egypt, when depression and bipolarity were mentioned in 
Eber’s papyrus (“Book of the heart”),  but are described as heart 
diseases and not mental disorders (Okasha and Okasha 2000).  
Over time, in most societies mental illness was attributed to 
magical forces, malevolent deities or demons and ‘treatment’ was 
exercised by priests in the form of religious or magical rituals.   
Hippocrates, Galen and Aretaeus of Cappadocia were the first to 
describe manic-depressive illness as a mental disorder.  
Hippocrates hypothesized that yellow bile caused manic rage 
while black bile (which was under the influence of the planet 
Saturn and related to autumn) caused melancholia- which 
constitutes the first biological model of a mental disorder. Long-
lasting anxiety, fear and moodiness were described as core 
characteristics of melancholia, while mania was believed to be 
caused by excess of blood. 
Ancient Greeks described melancholia as a state of aversion to 
food, despondency, sleeplessness, irritability, and restlessness 
 
 
and they also recognized the close relationship between 
depression and anxiety. Furthermore, “scientific” therapeutic 
interventions, such as personal hygiene, bathing and dieting, were 
proposed in order to “keep the humors in balance”, as well as 
more aggressive techniques, such as purgatives, cathartics and 
bleeding, were performed in “difficult-to-treat patients” or in 
cases of emergency in order to reset the balance of humor. 
Psychological treatments were also available, consisting in 
interpretation of dreams and talking to patients in attempt to 
encourage, console, and explain the illness (Plato's dialectics). 
Aretaeus of Cappadocia has established a connection between 
melancholy and mania and described manic episodes in a very 
similar manner to the modern one, including the description of 
psychotic features and seasonality. 
 During the 10th and 11th century AD, the Arab scholars 
dominated in the field of mood disorders, while in 1621, Robert 
Burton wrote the first English-speaking text on the field of mood 
disorders the “Anatomy of Melancholy”. Later, the works of 
Jean-Philippe Esquirol, Benjamin Rush, Henry Maudsley, Jean-
Pierre Falret and Jules Gabriel Francois Baillarger finally 
established the connection between depression and mania 
 
 
(Fountoulakis et al., 2012). 
In 1851 Falret defined bipolar disorder as an illness and coined 
the term "folie circulaire" (circular insanity) and in 1854 he 
established a link between depression and suicide. He recognized 
that this disorder is different from simple depression, and finally 
in 1875 his recorded findings were termed Manic-Depressive 
Psychosis, a psychiatric disorder. Another less well-known fact 
attributed to Falret is that he found that the disorder was more 
frequent in certain families, thus recognizing the existence of a 
genetic link (Fountoulakis, personal communication, 2012). 
In 1899, Emil Kraepelin established manic-depressive illness as a 
distinct nosological entity and separated it from schizophrenia, on 
the basis of heredity, longitudinal follow-up and a supposed 
favourable outcome. In clinical terms, Kraepelin suggested that 
depression is characterized by lowered mood and physical and 
psychomotor retardation while on the contrary while mania is 
characterized by elevation and acceleration of these processes.  
He also described ‘involutional melancholia’ as a form of 
agitated mixed state. Kraepelin conceptualized three basic 
dimensions (fundamental symptoms) of Bipolar Disorder, 
concerning mood (euphoria vs. depression), cognition (flight of 
 
 
ideas vs. thought slowing) and physical activity (hyperactivity vs. 
retardation). He proposed that these three dimensions fluctuate 
independently, and the different combination patterns that arise 
correspond to different mood episodes.  
Whereas melancholia today is seen as a mood disorder, in the 
nineteenth century it was viewed as insanity where the patient 
presented with an inhibition of activity, in contrast to mania, 
where the patient was overactive and raving.  
Esquirol introduced the notion of a mood disorder, as something 
quite distinct from mania and melancholia. He was the first to 
conceive of the possibility that a mood faculty could be disturbed 
separately, regardless of whatever else might be wrong with the 
patient. 
Kraepelin’s work was to grow in importance for psychiatry 
through the twentieth century, eclipsing first the work of 
Wernicke and his successors in Germany, then that of Esquirol 
and his successors in France, and finally that of Freud, Carl Jung, 
and the dynamic psychotherapists in the United States in the 
1980s (Fountoulakis et al., 2012). 
In terms of treatment, Bipolar Disorder is related to the earliest 
progress in psychopharmacology which in turn had enormous 
 
 
impact not only on psychiatry but also on philosophy, ideologies 
and social life. In the absence of knowledge about the etiology of 
a condition, supplementing a study of the symptoms of a disorder 
with a study of its longitudinal course might lead clinicians to 
real disease entities (Healy, 2002). 
Regarding the treatment of bipolar disorder, in 1843 Alexander 
Ure  introduced lithium into medicine by showing that  in vitro 
an uric acid bladder stone lost weight in a lithium carbonate 
solution and by the work of Sir Alfred Baring Garrod who 
discovered that gouty uric acids which deposit in finger joints are 
soluble in vitro in a lithium solution. On these bases, Armand 
Trousseau and Alexander Haig have suggested that mania and 
depression may be related to the uric acid nosology.    
As a matter of fact, modern psychopharmacology commenced 
with the use of lithium for the prophylaxis of recurrent 
depression by Karl Georg Lange in 1886, for acute depression 
and milder bipolar cases by Frederik Lange in 1894 in Denmark, 
and for the treatment of mania by William Alexander Hammond 
in the US.  
From the late 1880, lithium was available in the form of 
therapeutic mineral spring waters and lithium tablets. Cases of 
 
 
severe intoxications by lithium emerged, resulting in cases of 
deaths, and in 1949 lithium products were removed from the 
market. 
 After the World War II, John Cade injected urine from patients 
to guinea pigs to test the hypothesis that mania is caused by 
intoxication by a normal body element circulating in excess, 
whilst melancholia would be determined by its reduction. The 
guinea pigs would appear to die faster than when healthy persons' 
urine was used, leading him to think that perhaps more uric acid 
was present in the samples provided by his mentally ill patients. 
Then, in an effort to increase the water solubility of uric acid, 
lithium urate was added to the solution. Cade found that in the 
guinea pigs injected with the lithium urate solution, toxicity was 
greatly reduced. However, the control group in his experiments 
revealed that the lithium ion had a calming effect by itself. After 
ingesting lithium himself to ensure its safety in humans,  Cade 
began a small-scale trial of lithium citrate and/or lithium 
carbonate on some of his patients diagnosed with mania, 
dementia præcox or melancholia, with outstanding results. The 
calming effect was so robust that Cade speculated that mania was 
caused by a deficiency in lithium.  
 
 
 In 1949 Cade reported positive results in 10 manic patients 
(Cade 1949), however two years later he reported the first death 
because of lithium toxicity in a patient whose bipolar illness 
otherwise responded extremely well to treatment. Toxicity of 
lithium, that lead to several deaths (before the suitable tests to 
measure the lithium level in the blood were developed), 
alongside with the fact that lithium is a naturally-occurring 
chemical, thus lithium salt could not be patented, meaning that its 
manufacturing and sales were not considered commercially 
viable, lead to abandon lithium use for the second time. In fact, 
hese factors prevented its widespread adoption in psychiatry for 
some years, particularly in the United States, where its use was 
banned until 1970. 
 In the 1960s the first double blind trial in psychiatry, involving 
lithium, was conducted by Mogens Schou (Schou et al. 1954).   
Sharp criticism and reservation followed this publication and 
many prominent psychiatrists questioned lithium's effectiveness 
and emphasized its toxicity (Blackwell and Shepherd 1968; 
Shepherd 1970; Blackwell 1969, 1970, 1971, 1972). Only during 
the 1970s and after subsequent work by Paul Baastrup (Baastrup 
1964; Baastrup et al. 1970; Baastrup and Schou 1967) lithium 
 
 
was established in the treatment of bipolar disorder (Bech 2006; 
Schioldann 1999, 2011; Schioldann 2006). 
Following the success with lithium treatment, valproate was 
introduced in 1966 (Lambert et al. 1966) followed by 
carbamazepine (Okuma et al. 1979). Antipsychotics were 
introduced by Delay and Deniker in 1955 and  among the patients 
they treated probably many were bipolar patients with acute 
mania (Delay and Deniker 1955). Second generation 
antipsychotics were introduced and became widely accepted from 
2000, mostly due to their tolerability, in particular for the low 
incidence of tardive dyskinesia. Benzodiazepines were 
introduced by Sternbach in 1956. In 1958 Roland Kuhn reported 
on the efficacy of the first antidepressant, imipramine (Kuhn, 
1958). 
There were several reports in the 1970s suggesting that the use of 
antidepressants might induce mania, mixed episodes and rapid 
cycling. In 1994 American Psychiatric Association published the 
first operational treatment guidelines. Also, during this period the 
first meta-analytic studies emerged, and the Evidence-Based 
Medicine principles gained ground in the treatment 
recommendations (Fountoulakis, 2012, personal communication).  
 
 
2.1.2.  Epidemiology  and Course of illness 
Bipolar disorder (BD) is a chronic mood disorder affecting 
around 4% of adults (Merinkagas et al., 2007)  with a prevalence 
ranging from 1% (bipolar disorder type I) to 6.5% (bipolar 
spectrum disorders, including bipolar I and II disorders) in the 
general population (Vieta et al., 1997; Hirschfeld and Vornik, 
2004; Merikangas et al., 2007). Bipolar disorder is a severe, 
chronic and recurrent disorder with a high prevalence of 
subsyndromal interepisodic symptomatology (De Dios et al, 
2012; Bonnin et al., 2012) and a significant impairment in the 
affected individuals (Sanchez-Moreno et al., 2009; Rosa et al., 
2011). 
Bipolar disorder is recognized as one of the world’s 10 greatest 
public health problems (Murray and Lopez, 1997). Patients with 
bipolar I and II disorder spend half of their lifetime in a 
symptomatic state and almost all patients encounter high rates of 
affective recurrences (Dittmann et al., 2002, Joffe et al., 2004, 
Post et al., 2003). Despite the dramatic and life-disrupting nature 
of mania, some studies have documented that depressive 
episodes, rather than the manic ones, have the strongest impact 
on quality of life and functional outcome (Judd et al., 2005; Depp 
 
 
et al., 2006; Post, 2005; Hirschfeld, 2004).  
In studies that recruited only bipolar I patients, a depressive index 
phase predicts longer time needed to full remission, utter acute 
episodes, more time spent in any mood episode, and lower 
percentage of patients reaching full symptomatic and functional 
remission (Post, 2003; Nolen, 2004; Tohen, 2003). Patients with 
depressive symptoms have a higher suicidal rate and more 
suicidal behaviour (Valtonen et al., 2006; Galfalvy et al., 2006). 
Moreover, depressive symptoms are responsible for an increased 
risk of somatic illnesses, such as obesity and cardiovascular 
disease, therefore reducing overall life expectancy (Disease et al., 
1997; Fagiolini et al., 2002; Mitchell and Malhi, 2004).  
Two of the reasons for the improvement of prognosis in this 
population are the steady and substantial decrease of 
misdiagnosis of bipolar type I disorder as schizophrenia or 
unipolar depression, as well as the fact that the most recent 
classification systems, DSM-IV-TR and ICD-10 have made the 
diagnosis of manic-depressive disorders more inclusive. The 
further subdivision of bipolar mood disorders into bipolar I 
(depression with a history of mania or mixed episode) and 
bipolar II (depression with history of hypomania, but not with 
 
 
mania) was proposed almost 30 years ago (APA, 1994, WHO, 
1991). Since then, several studies have demonstrated that bipolar 
II disorder represents a quite common, clinically and biologically 
distinct form of affective disorders that should be differentiated 
from both bipolar I disorder and unipolar major depressive 
disorder (Akiskal and Mallya, 1987) and that it leads to similar, 
sometimes even worse, psychiatric and social consequences than 
bipolar I and unipolar patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.3.  Clinical characteristics and diagnosis 
The diagnosis of bipolar disorders is based on clinical criteria 
which are hence subject to controversy and interpretation. 
Nonetheless, bipolar disorders (especially type I) have a greater 
validity of construct and long-term stability than those of other 
mental disorders. The manic states are typically characterized by 
elated mood, increment in quantity and speed of speech,  quicker 
thought, increased psychophysical activity, greater energy (with a 
corresponding decrease of need to sleep), irritability, perceptual 
acuity, paranoia, hypersexuality and increased impulsivity. The 
degree of type and duration of these cognitive, perceptual, 
behavioural and neurovegetative alterations determine the 
distinction between hypomania and mania. In hypomania, the 
abovementioned changes are generally moderate and may or may 
not result in serious problems for the individual experiencing 
them, and may even determine increased productivity and are 
often seen as egosyntonic and subjectively pleasant. In more 
intense episodes, however, they can disrupt the lives of the 
patients, their families, and social functioning. Hypomania is a 
very labile condition which often evolves into full-blown mania 
or is followed by depression, also facilitated by increased alcohol 
 
 
and substance misuse during the episodes. 
The bipolar depressive states, in sharp contrast to the manias, are 
usually characterized by a slowing or decrease in almost all 
aspects: rate of thought and speech, energy, sexuality, and the 
ability to experience pleasure or sometimes even emotions. The 
depressive phase of bipolar disorder is often accompanied by 
apathy predominating over sadness, psychomotor inhibition over 
anxiety, hyperphagia rather than hyporexia, hypersomnia over 
insomnia.  
According to DSM-IV-TR, mixed episodes are defined as the co-
existence of both depressive and manic symptoms to the extent 
the criteria for both a manic and a depressed episode are fulfilled, 
while in contrast the ICD- 10 definition considers it as either a 
mixture or a rapid alternation (i.e. within a few hours) of 
hypomanic, manic and depressive symptoms. In real-life clinical 
setting, most patients present a mixture of a number of manic and 
depressive symptoms in a combination which does not fulfil the 
DSM criteria for a manic, depressive or mixed episode, and thus 
could be diagnosed in the cathegory of  not-otherwise-specified 
(NOS) mood episode (Fountoulakis et al., 2012). 
As abovementioned, according to formal classification, bipolar 
 
 
disorder consists of at least one manic (Bipolar Disorder I), 
hypomanic (Bipolar Disorder II) or mixed episode and a 
depressive episode.   
The term “rapid cycling” refers to patients suffering from at least 
4 mood episodes in a year. It seems more frequent in female 
patients and in higher social class subjects (Fountoulakis et al., 
2012). 
Psychotic features are common in bipolar patients and may 
include delusions or hallucinations of any type, and they can be 
mood-congruent or even non-congruent, and both could occur in 
the context of any type of episode. In fact, the diagnostic criteria 
for schizoaffective disorder according to DSM-IV-TR require the 
presence of a psychotic episode in the absence of prominent 
mood symptoms.  
BD also presents significant rate of psychiatric comorbidity, 
according to most studies with a prevalence of 50% -70% (Vieta 
et al., 2001) or even higher. The presence of comorbidities is 
associated with worse prognosis, more severe subtypes, earlier 
onset, lower remission rates, suicidal behaviour, lower response 
to treatment, worse functioning and quality of life (Vieta et al., 
2012; Pacchiarotti et al., 2009: Vieta et al., 2001; Nery-Fernandes 
 
 
et al., 2009). The most common psychiatric comorbities of 
bipolar disorder are represented by anxiety and substance abuse 
disorders (Vieta et al., 2012). 
 Alcohol abuse could be present in more than half of the patients 
and frequently represents self-medication efforts. The drug abuse 
pattern of bipolar patients concerns mainly stimulants (Winokur 
et al., 1998). Cognitive impairment is reported to exist in both 
Bipolar I and Bipolar II patients, with a higher frequency among 
bipolar I patients,  and it is present in all phases of the disorder, 
even during euthymia (Sole et al., 2011, Malhi et al., 2004). 
Various studies suggest that there is a significant degree of 
psychosocial impairment even when patients are euthymic and 
report that only a minority achieves complete functional recovery 
(Daban et al., 2006; Mur et al., 2004). 
The correct diagnosis is frequently made only after several years 
from the onset, since the first episode is often depressive and the 
correct diagnosis is made only after a manic or mixed episode 
emerges. More than half of the patients with depressive onset will 
be diagnosed as bipolars within the following 20 years (Angst et 
al., 2005), indicating the misdiagnosis of the first episode(s) as 
unipolar depression.  
 
 
A number of illness features have been proposed to indicate risk 
of bipolar disorder in the context of a depressive episode, 
including earlier age of illness onset, greater number of 
depressive recurrences or briefer episodes, family history of 
bipolar disorder and aspects of temperament such as hyperthymia 
and cyclothymia. Regarding the symptoms, indicators of 
bipolarity are presence of irritability or anger, presence of 
psychotic symptoms, suicidality, and atypical neurovegetative 
symptoms including psychomotor agitation or slowing. 
Moreover, even in individuals who do not meet full syndromal 
criteria for bipolar I or II disorder, it has been suggested that 
these illness features may be markers for an underlying bipolar 
diathesis or bipolar spectrum illness (Perlis et al., 2011). This 
goes much beyond academic interest, with profound implications 
for the treatment and its overall efficacy. An additional problem 
for the diagnosis is that patients usually experience hypomania as 
a recovery from depression, often a pleasant egosyntonic mood 
state, which may pass unobserved by the clinicians and 
unreported by the patient himself.  
 
 
 
2.1.5. The clinical implications of cognitive impairment and 
allostatic load in bipolar disorder   
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A B S T R A C T
Background: Allostatic load (AL) relates to the neural and bodily ‘‘wear and tear’’ that emerge in the
context of chronic stress. This paper aims to provide clinicians with a comprehensive overview of the role
of AL in patophysiology of bipolar disorder (BD) and its practical implications.
Methods: PubMed searches were conducted on English-language articles published from 1970 to June
2011 using the search terms allostatic load, oxidative stress, staging, and bipolar disorder cross-
referenced with cognitive impairment, comorbidity, mediators, prevention.
Results: Progressive neural and physical dysfunction consequent to mood episodes in BD can be
construed as a cumulative state of AL. The concept of AL can help to reconcile cognitive impairment and
increased rates of clinical comorbidities that occur over the course of cumulative BD episodes.
Conclusions: Data on transduction of psychosocial stress into the neurobiology of mood episodes
converges to the concept of AL. Mood episodes prevention would not only alleviate emotional suffering,
but also arrest the cycle of AL, cognitive decline, physical morbidities and, eventually, related mortality.
These objectives can be achieved by focusing on effective prophylaxis from the ﬁrst stages of the
disorder, providing mood-stabilizing agents and standardized psychoeducation and, potentially,
addressing cognitive deﬁcits by the means of speciﬁc medication and neuropsychological interventions.
 2011 Elsevier Masson SAS. All rights reserved.
Available online at
www.sciencedirect.com1. Introduction
The term ‘‘allostatic load’’ was introduced by McEwen and
Stellar [86] to refer to a cumulative, multisystem view of the
physiologic toll that is required for adaptation to stress. Although
adaptive mechanisms of allostasis can be protective for the
individual, there is a price to pay for this forced re-setting of
parameters, especially if allostatic processes become extreme or
inefﬁcient. The cost of these processes is called allostatic load. In
other words, it is the ‘‘wear and tear’’ on the body and brain
resulting from chronic over-activity or inactivity of physiological
systems that are involved in adaptation to environmental
challenges [87]. The effects of allostatic load (AL) are cumulative
and most notably seen during the process of aging and chronic
stress. Subjects with highest AL were found to have increased risk
for incident cardiovascular disease, physical and cognitive decline,* Corresponding author. Tel.: +34 93 2275401; fax: +34 932275795.
E-mail addresses: evieta@clinic.ub.es, jose.sanchez.moreno@cibersam.es
(E. Vieta).
Please cite this article in press as: Vieta E, et al. The clinical implicatio
European Psychiatry (2012), doi:10.1016/j.eurpsy.2011.11.007
0924-9338/$ – see front matter  2011 Elsevier Masson SAS. All rights reserved.
doi:10.1016/j.eurpsy.2011.11.007and all-cause mortality in cross-sectional and follow-up studies
[57,56,58,135,134,133].
Neurocognition has been the focus of extensive research in
schizophrenia and, more recently, in bipolar disorder (BD)
[29,39,73,76,115,129]. Neuropsychological testing may represent
a tool able to identify potential neuroimaging markers and
endophenotypes [23,46,124,149] and to better understand the
underlying neurophysiology [49]. However, only lately the highly
consistent ﬁndings from research began to be applied to clinical
practice, and many clinicians are not much aware of how
neurocognitive deﬁcits affect their patients’ daily life, and,
importantly, what can be done to prevent or at least mitigate
cognitive impairment. Recent evidence suggests that neurocogni-
tive status may be the most powerful predictor of functional
outcome in BD, even more so than clinical features [80].
Bipolarity, as a severe form of mood disorder, cognitive
impairment, and increased physical morbidity and mortality,
converge in the concept of allostatic load.
The present paper deals with the most recent ﬁndings
connecting cognition, physical health, comorbidity and functional
outcome in BD. Particular emphasis is made on what the clinicianns of cognitive impairment and allostatic load in bipolar disorder.
E. Vieta et al. / European Psychiatry xxx (2012) xxx–xxx2
G Model
EURPSY-3003; No. of Pages 9can do to prevent or possibly reverse the detrimental effects of AL
and its impact on patients’ lives.
A PubMed search of the literature, using search terms ‘‘allostatic
load’’ and ‘‘bipolar disorder’’ cross-referenced with ‘‘cognitive
impairment’’, ‘‘comorbidity’’, ‘‘mediators’’, and ‘‘prevention’’, was
performed. The search was supplemented by manually reviewing
reference lists from the identiﬁed publications. Only English-
language articles published from 1970 to July 2011 were included.
The results of this search are presented in this article and examined
under the light of a unifying hypothesis, together with some
suggestions for further research in this intriguing area.
2. Allostatic load and its mediators
The concept of AL may help to integrate apparently unrelated
ﬁndings among bipolar patients such as vulnerability to stress,
cognitive impairment and higher rates of physical comorbidity and
mortality [53]. BD can be hypothesized as a disease of cumulative
allostatic states where AL increases progressively as mood
episodes occur over time. The mediators of AL include genes
[27], neurotrophic factors [128], neurotransmitters [83], hormones
[160], immune-inﬂammatory system [156] and oxidative stress
[15]. Hence, although essentially related to normal function and
protection of the brain, the mediators of allostasis are also
associated with increased risk of systemic damage and neuron cell
endangerment, when excessive [144]. All organs are subject to the
deleterious effects of AL, but the brain tissue appears to be
particularly vulnerable [131]. On the other hand, brain also exerts
an integrative role in the process of stress response, as it
orchestrates the action of several adaptive systems such as
cardiovascular, metabolic and immune systems through a seriesMood episode
Comorbid Pathologies
DNA 
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Fig. 1. Allostatic lo
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European Psychiatry (2012), doi:10.1016/j.eurpsy.2011.11.007of primary mediators, such as adrenal steroids, catecholamines,
dyhidroepiandrosterone (DHEA), prolactin, thyroid and growth
hormones, cytokines and neurotransmitters (Fig. 1). These
mediators inﬂuence cellular events through their action in
receptors, enzymes, second messenger systems and gene expres-
sion. The paradoxical role of the brain in triggering allostatic
processes and being vulnerable to its effects provides a suitable
model for cognitive decline in the context of neurodegenerative
disorders. It is plausible that a cycle of higher vulnerability of BD
patients and greater AL may account for the clinical decline and
poor outcomes described in more severe forms of bipolar illness.
The structural and functional changes in the brain associated
with aging and the cognitive decline associated with chronic
elevated levels of glucocorticoids provide evidence of the long-
term burden caused by AL [83]. Adaptive plasticity is seen in
response to acute and chronic stress, as indicated by synaptic and
dendritic remodeling, neurogenesis, and atrophy of neural
structures, particularly in the hippocampus [36,82]. Repeated
stress is also related to decreased neurogenesis in the dentate
gyrus, and chronic administration of various classes of drugs
increases the neurogenesis in the dentate gyrus and hippocampal
hilus in rats [71]. Although essential to normal synaptic
neurotransmission, stress-induced dysfunctional activity of neu-
rotransmitter systems can lead to excessive formation of free
radicals that can damage neural cells [83]. Glucocorticoids and
mediators of allostasis interact with neurotransmitter systems and
brain peptides resulting in neuroplastic alterations seen in
hippocampus, amygdala and prefrontal cortex [85]. In addition
to the critical role of glucocorticoids in the hippocampus, AL is also
responsible for important alterations in other brain structures.
Chronic stress in animal models is related to abnormal neuronals 
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glial cells [34], and amygdala [165,164]. Structural and functional
magnetic resonance imaging studies in depression and Cushing’s
disease, as well as in anxiety disorders, provide evidence that the
human brain may be similarly affected [85]. If higher AL is
associated with higher mortality, morbidity and cognitive
impairment, identifying and addressing clinical biomarkers of
AL can have important biomedical implications [52].
Oxidative stress is one of the main mediators of AL. Recent
studies have reported alterations of biological markers of oxidative
stress in BD patients. Serum TBARS (thiobarbituric acid reactive
substances) levels were increased in all phases of BD, while
calcium binding protein B (S100B), associated to brain damage,
increments in mania and depression, but not during euthymia. The
damage seems to be more evident in mania [4]. Alteration in
intracellular signaling pathways within the mitochondria may be
associated with cell apoptosis in response to oxidative stress [14].
Oxidative stress plays a key role in the induction of DNA damage,
endothelial dysfunction and telomere shortening [53]. BD out-
patients present an increased frequency of DNA damage when
compared to controls [5]. The frequency of DNA damage correlates
with the severity of symptoms of depression and mania. Both
depressed and euthymic bipolar patients present impairment of
endothelial function due to oxidative stress, which may increase
risk for cardiovascular conditions [125]. Oxidative stress is also
implicated in accelerated telomere shortening [127]. Accelerated
telomere shortening was also detected in individuals with BD.
Taken together, these studies suggest that chronic oxidative stress
associated with mood disorders may contribute to excess
vulnerability for aging-correlated diseases such as cardiovascular
pathology [138].
Another potential source of oxidative stress in BD is dopami-
nergic system alteration during manic episodes [15] and distorted
homeostasis of dopamine receptor subtypes in bipolar patients
[107,163]. Treatment with antipsychotic medication is associated
with a downregulation of D1 receptor expression [68] and increase
of D3 receptors [163]. Signal transduction pathways activated by
oxidative stress have been implicated in mood disorders and in
several chronic medical disorders such as obesity, diabetes and
cardiovascular disease [90].
Some of the changes in brain morphology described to be
associated with AL have also been reported in patients with BD. It is
noteworthy that some growth factors, which are altered by stress,
have been also shown to be changed in BD. This is particularly true
in the case of a particular protein involved with neuroplasticity and
neurogenesis, the brain-derived neurotrophic factor (BDNF) [113].
It has been recently demonstrated that serum BDNF levels
decrease during both manic and depressive episodes. Moreover,
BDNF levels were negatively correlated with severity of manic and
depressive symptoms [33,69]. In addition, a single polymorphism
of the BDNF gene (Val66Met) has been associated with impaired
cognitive performance [123] and increased risk to rapid cycling
[48,97] in BD patients. Euthymic patients (both val/val and met
carriers for the BDNF gene) had similar serum BDNF levels in
comparison to controls, suggesting that the normalization of BDNF
levels may be associated with mood stability [155]. Serum
neurotrophin-3 and glial cell line-derived neurotrophic factor
levels, though, are increased during acute mood episodes
[120,166], which may indicate a compensatory response to BDNF
decrease. Some of the brain structural changes that have been
described in BD, such as enlargement of amygdala and reduction in
the size of prefrontal cortex and hippocampus [11,18,96], may in fact
reﬂect enduring malfunction patterns of circuits involved in
conferring the emotional valence of experiences [111]. If the gate
system to code experiences as stressful is overactive and defective,
such malfunctioning would render bipolar patients more vulnerablePlease cite this article in press as: Vieta E, et al. The clinical implicatio
European Psychiatry (2012), doi:10.1016/j.eurpsy.2011.11.007to stress and its neurobiological consequences, therefore increasing
susceptibility to trigger AL.
3. Cognitive impairment in bipolar disorder
There is indisputable evidence that BD is associated with
signiﬁcant neurocognitive deﬁcits across all mood states [78].
Cognitive deﬁcits persist during euthymia and may include
attention, executive function and verbal memory impairment
[77,98,119]. These cognitive dysfunctions may reﬂect abnormal
activation patterns in the brain [13,142], implicating the prefrontal
cortex in the etiopathogenesis of bipolar illness and positing
cortical-subcortical-limbic disruption as the underlying cause
[72,104]. Such deﬁcits do not seem to be speciﬁc and their pattern
is quite similar to schizophrenia, albeit overall less severe [35].
Euthymic bipolar patients demonstrate relatively marked
impairment in executive function and verbal memory [119]. It is
not clear yet whether these are two discrete areas of impairment or
are inter-related. In addition, is yet to be determined whether
neuropsychological impairment is present in premorbid state,
although several studies suggest that bipolar patients may be
relatively preserved from the neurocognitive point of view before
developing their condition [67]. Several studies have assessed
cognitive performance of large cohorts of children or youth and
analyzed the speciﬁc proﬁle of those who would subsequently
develop BD or schizophrenia; overall, there is no suggestion for
severe premorbid deﬁcits, whereas there seems to be so for
schizophrenia [25,117,170] perhaps with the exception of
visuospatial reasoning [152]. Interestingly, subjects at risk for
BD were more likely than subjects at risk for schizophrenia and
even than subjects at no risk for mental disorders to perform better
in some domains [25], particularly at arithmetic reasoning [152].
Neuropsychological studies on ﬁrst-degree relatives of subjects
with BD, though, suggest that there might be some mild deﬁcits
underlying vulnerability to the disorder in the areas of psychomo-
tor speed and executive function [7,9,147], but not verbal memory
[30]. In fact, verbal memory was not found to be related to
increased risk for BD in premorbid neuropsychological studies
[152], but seems to be strongly affected by the impact of multiple
episodes [77], subthreshold depressive symptoms [92], and
medication [19,79]. Hence, verbal memory may be a potential
treatment target by means of effective prophylactic treatment,
improvement of subclinical depressive symptoms, and rational use
of medication. Importantly, verbal memory performance has been
reported to be highly correlated with functional outcome [3,80].
Neurocognitive impairment may not occur exclusively in
individuals with BD I, as it has also been reported in BD II [153],
schizoaffective disorder bipolar type [154], bipolar patients with
and without history of psychosis [19,81,136], bipolar suicide
attempters [50], bipolar patients with comorbid conditions
[122,157], and pediatric BD [109]. On the other hand, a subset
of bipolar patients seems to have little or no cognitive impairment
[2]. Thus, the study of bipolar subtypes and subgroups, including
those who do not show cognitive deﬁcits, may provide important
clues for the effective treatment and prevention of cognitive
impairment and psychosocial dysfunction.
The number of longitudinal studies on the course and outcome
of cognitive dysfunctions in BD is very limited. Although there is
evidence that multiple episodes carry more cognitive impairment
[10,61], in particular the manic episodes [78], only a few studies
have addressed this issue in a prospective, longitudinal design.
Neuroimaging studies are also mostly cross-sectional, although
there is evidence that patients with multiple episodes, and
especially more manic episodes, are more likely to have enlarged
ventricles and gray matter atrophy than ﬁrst-episode patients
[141]. Data from the few longitudinal studies available suggestns of cognitive impairment and allostatic load in bipolar disorder.
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improve little over time [8,41,88,99,150], but they do not seem to
lead to any sort of dementia-like syndrome [38].
Neurocognitive symptoms are not only important because they
tell us about the brain areas and functions involved in the
pathogenesis of the disease and represent potential endopheno-
types, but also for their clinical value; there is an ongoing debate on
to what extent they should be included in the diagnostic criteria for
schizophrenia [60] and BD [158]. Interestingly, there is no perfect
match between cognitive impairment as reported by the patients
and as assessed with neuropsychological tools [22,79]. Subjective
cognitive impairment may be more closely related to enduring
subthreshold depressive symptoms and/or medication side-effects
[79,162] than objective impairment, which would be associated to
the endotoxic effects of mood episodes and AL [53]. This sort of
‘‘true’’ cognitive dysfunction would be close to the concept of
anosognosia [44] and the type of deﬁcits that can be seen in
neurodegenerative conditions.
Medication may play an important role in the etiology and
also in the treatment of cognitive problems. Most studies are
unable to disentangle the potential effects of medication on
cognition, because patients are usually medicated. Extrapyrami-
dal, anticholinergic, anticonvulsant, and sedative effects of
medications may affect some of the cognitive functions. There
have been claims that some medications might improve
cognition in psychosis, but the results were confounded by
parallel clinical improvement. There is little, if any, evidence that
medication by itself may help to improve cognition. Studies in
healthy volunteers have evidenced that lithium therapy is
associated with small but signiﬁcant impairment in immediate
verbal learning, memory and creativity [168]. Both lithium and
valproate decrease blood-oxygen-level-dependent (BOLD) signal
magnitude during various tasks in distinct brain regions in
healthy volunteers [12]. Studies in non-medicated bipolar
subjects exist [151], but they are difﬁcult and often confounded
by severity bias, as non-medicated patients tend to be less severe
than those who cannot discontinue treatment. Although some
medications might have a better proﬁle regarding cognitive side-
effects, there is little evidence to support this claim so far for any
speciﬁc compound [42]. The area of potential therapies, both
pharmacological and psychosocial, particularly targeted to
improve cognitive dysfunctions, will surely quickly develop in
near future [24,159].
Whatsoever, structural abnormalities were reported to be
present in bipolar children and adolescents [110] suggesting that
these are not due to the effects medication or multiple mood
episodes.
Finally, cognitive dysfunction may also be inﬂuenced by
psychosocial factors, such as inability to fulﬁll academic achieve-
ments, decreased reading time and cultural interests, and decades
ago, by institutionalization. Most studies try to search for these
factors, and it is still unclear whether they can actually help, if
reversed, to remediate some cognitive deﬁcits [108].
4. Staging
As previous studies have shown, alongside with decrease in
BDNF levels during mood episodes [33,137], multiple episodes
may impair the restoration of the levels of BDNF [59]. This ﬁnding
is in agreement with the evidence of better clinical outcome for
patients at early stages of illness [130], better treatment response,
especially to lithium [145] and olanzapine [63], longer duration of
euthymia in interepisodic periods [62]. Based on these observa-
tions, a staging model was proposed by Berk et al., [15] and
elaborated by Kapczinski et al. [55].Please cite this article in press as: Vieta E, et al. The clinical implicatio
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and differentiate treatment strategies according to stages. The
progression of BD is staged according to the spectrum that presents
prodromal stages at one end, and refractory clinical presentations,
which could culminate with persistence of unremitting illness on
the other end. The progression is facilitated by the cumulative
exposure to acute episodes, substance abuse, life stress summed
with inherited vulnerability [53]. The failure of compensatory
mechanisms following the exposure to environmental stressors
and the subsequent cumulative mood episode-related toxicity may
account for lower life expectancy in bipolar patients [55,102]. The
staging model has important clinical implications, proposing early
intervention and neuroprotective strategies in early phases, while
the latter stages may require more rehabilitative interventions.
Recently, Kapsczinski et al., [54] have suggested the need to
include neurobiological parameters/biomarkers, assessment of
neurocognition, psychosocial functioning and autonomy alongside
the longitudinal evaluation of clinical variables. This approach will
utterly facilitate a better understanding of the mechanisms
underlying progression of BD and ameliorate treatment strategies.
5. Prevention and treatment of cognitive and allostatic load
correlates in bipolar disorder
The implication of AL in provides the grounds for further
hypothesis of its role in determining cognitive impairment [78],
medical [26], and psychiatric comorbidity [93,161].
5.1. Allostatic load correlates: medical comorbidity
BD is highly comorbid with a wide range of medical disorders,
such as cardiovascular, metabolic, infectious, neurological and
respiratory [26]. According to many studies, BD is associated with
higher rates of mortality for all natural causes except cancer [26].
The lack of increased oncological risk may be secondary to
potential anti-cancer properties of mood stabilizers as well as
other mediators of negative comorbidity [148]. Valproate has an
antiproliferative and differentiating effect in vitro and in vivo, with
potential oncological beneﬁts [139]. Recent in vitro studies have
evidenced antiproliferative action of lithium as well [105,143].
AL may play a role in physical and cognitive decline,
cardiovascular disorders [133], immunity impairment, obesity,
bone demineralization and atrophy of cerebral nerve cells [84],
whose association with BD is well established. There is evidence
that reduction in AL is associated with lower all-cause mortality,
even in geriatric patients [58], and should therefore represent a
treatment target in all age groups.
Drugs implied in treatment of BD also play a role in medical
comorbidity. Second-generation antipsychotics are associated
with increased risk of weight gain, diabetes mellitus and
cardiovascular disease [89,101]. On the other hand, mood
stabilizers [6,43,69] and SSRIs, often prescribed in adjunction to
mood stabilizers in bipolar depression, can diminish AL secondary
to depressive episodes as well as oxidative stress [64,169] and
therefore may decrease medical comorbidity, especially in Bipolar
II disorder [90], although the evidence supporting their efﬁcacy in
that condition is still very weak.
5.2. Allostatic load correlates: psychiatric comorbidity
BD also presents signiﬁcant rate of psychiatric comorbidity.
Most studies report prevalence between 50% and 70% [161] or
higher [93] with one recent study reporting lower lifetime
prevalence of 27.4% in euthymic patients [100]. The presence of
comorbidities is associated with worse prognosis, more severens of cognitive impairment and allostatic load in bipolar disorder.
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lower response to treatment, worse functioning and quality of life
[91,100,161]. Most frequent comorbidities are represented by
substance use disorders and anxiety disorders [93]. A growing
body of evidence indicates that some of the neuroadaptive changes
that occur in ‘‘brain stress systems’’ in patients with addiction [66]
are comparable to those described as associated with AL. Therefore
we suggest that substance abuse should be seen as a mediator of
AL. In fact, Maremmani et al., [74] have proposed that bipolar
spectrum disorders and addiction should be considered under a
unitary perspective as they often co-occur and constitute
reciprocal risk factors while stressing the need to combine opiate
agonists with mood-stabilizing therapy. Pacchiarotti et al., [106]
have hypothesized the existence of a subtype of BD in which
substance misuse may trigger, and perhaps maintain, mood
symptoms in vulnerable individuals. These individuals would
beneﬁt from primary prevention programs as well as psychoedu-
cational strategies [31] combined with pharmacotherapy.
5.3. Cognitive impairment
Patients with BD frequently display subthreshold symptoms
[62] and cognitive impairment [78] during all phases of BD. The
persistence of cognitive function impairment contributes, along-
side multiple mood episodes, to exacerbate AL [53]. Cognitive
impairment, especially verbal memory function, predicts reduced
psychosocial functioning [80] and represents a potential target of
prophylactic treatment.
Neurotrophins and inﬂammatory cytokines such as TNF-a
can be considered as neurobiological markers implicated in
neurodegeneration and cognitive impairment in BD [37,65].
BDNF and lithium, through the phosphatidylinositol pathway are
able to neutralize glutamate-stimulating effects of TNF-a and
other inﬂammatory mediators [1,59]. Several studies have
pointed out that mechanism of action of mood-stabilizing
medication may include cyclooxygenase2 (COX-2) inhibition
and reduction in inﬂammatory cytokines [20,45,116]. As
previously mentioned, it has been demonstrated that chronic
treatment with lithium and valproate can inhibit oxidative
damage [6,43,69] and thus may play a role in preventing
cognitive impairment due to AL. Recent evidence suggests that
lithium determines a decrease in pro-inﬂammatory mediators in
BD, but not among non BD subjects [47]. Another pathway by
which lithium may provide enhancement of learning and
memory [103,167] might include stimulation of BDNF, reported
as reduced during manic and depressive episodes [33,69], bcl-2
production, and inhibition of GSK-3beta [121,126]. Since BDNF
expression is altered in BD and under stress, we can speculate
that lithium, through enhancement of BDNF, is able to diminish
AL correlates in BD.
Family intervention, CBT, group psychoeducation, interpersonal
social rhythm therapy have shown good prophylactic efﬁcacy
when combined with pharmacotherapy in BD [94]. Psychoeduca-
tion for caregivers has also shown to improve illness outcome,
especially in the early stages [118].
5.4. Multiple episode cumulative damage
In order to characterize changes in the cognitive-affective
evolution over time in BD and its progression from prodromal
phase to a clear-cut clinical disorder, and at times to a resistant
condition, various models have been proposed [140]. These include
neurosensitization [114], staging and AL theories.
In the early 1990s, Post has put forward the ‘‘kindling theory’’
according to which biochemical and anatomical substrates
underlying the affective disorders evolve over time as a functionPlease cite this article in press as: Vieta E, et al. The clinical implicatio
European Psychiatry (2012), doi:10.1016/j.eurpsy.2011.11.007of recurrences, favouring new episodes on one hand and reducing
pharmacological responsivity on the other [112].
In BD, the cumulative damage from persistent AL probably
sums up to kindling and sensitization mechanisms deriving from
multiple recurrences [53]. Patients with more previous mood
episodes were reported to present higher comorbidity rates,
especially substance abuse, poorer social adjustment, increased
risk of hospitalization, suicide rates and forensic complications
[17]. Similar trend was detected also among children and
adolescents with BD- those with multiple episodes per year
presented a higher comorbidity, in particular Attention Deﬁcit
Disorder, and required more hospitalizations and pharmacological
treatment than those without multiple episodes [28].
Recurrent episodes may inﬂuence the outcome by creating
utter vulnerability to subsequent episodes as well as by reducing
the response to therapy [63]. In addition, response to lithium is
inversely correlated to number of episodes [145] and duration of
illness prior to starting treatment [70]. Consistently, olanzapine
was found more effective early in the course of BD [63]. The same is
true for psychotherapy; patients with multiple recurrences do not
seem to respond to adjunctive cognitive-behavioural therapy
[132]. Similarly, the number of previous episodes clearly appears
to reduce the response to psychoeducation, although perhaps in a
more subtle way than that observed in cognitive-behavioural
therapy [32].
In a recent study [17] have evidenced that both response to
treatment rates and relapse rates were more favourable in patients
with fewer mood episodes, the best being for patients with one to
ﬁve lifelong episodes, followed by the group with ﬁve to ten
episodes, the least favourable being for patients with more than
ten episodes.
Together, these results suggest that neuroplastic changes
associated with the progression of illness can negatively affect
treatment success.
6. Limitations and conclusions
While there is evidence of structural abnormalities in bipolar
disorder, indicating dysfunction in subcortical (striatal-talamic)
and limbic regions, observable early in the course of the illness
which suggests that they are not merely the sequelae of recurrent
affective episodes or pharmacotherapy, and a growing under-
standing of the molecular mechanisms that may underpin these
abnormalities [140], the psychobiological models still present
various gaps. Deﬁning biomarkers according to stages of bipolar
disorder, still largely lacking, would be useful to ameliorate
diagnostic validity and clinical utility of the proposed models. It is
not yet clear to which extent it is possible to reverse the
progression of bipolar disorder, whether a Stage 4 patient can
go back to Stage 3, or even 2. Nevertheless, the proposed models
provide valuable indications for treatment strategies and future
research.
Prompt intervention is necessary since the onset of prodromal
symptoms in individuals at high risk for developing BD, as
indicated, for instance, by presence of family history [40]. At this
stage, psychoeducation strategies should focus on avoidance of
environmental stressors such as substance misuse [54] and early
recognition of ﬁrst-episode symptoms. Long-term treatment from
the ﬁrst episode, alongside with psychosocial and psychoeduca-
tional approaches addressing compliance to medication and
prevention of secondary sequelae [16], including education on
the disorder, healthy life style habits and physical exercise [146]
may help to arrest the cycle of AL and neuroprogression, which
complicates the illness course by contributing to cognitive
impairment and comorbid pathologies (Table 1).ns of cognitive impairment and allostatic load in bipolar disorder.
Table 1
Actions with potentially positive effects for the prevention of cognitive impairment
and allostatic load in Bipolar Disorder (‘‘Change Compass’’).
Cognitive Remediation
Healthy diet
Antioxydants
N-acetyl-L-cysteine (NAC)
Good sleep
Exercise
Comorbidities rigorously treated
Omega-3
Mood Stabilizers
Psychoeducation
Avoid overprescription
Subthreshold symptoms rigorously treated
Substance misuse avoidment
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may help to arrest the cycle of affective episode recurrence and
neural and bodily deterioration [53]. All stages of disorder require
adequate mood stabilization, if necessary with more than one
mood stabilizer or with adjunction of an atypical antipsychotic in
order to prevent recurrences. Diminishing AL and its dramatic
correlates, that inﬂuence cognitive and functional impairment
and correlate to psychiatric and medical comorbidities and
related mortality should be considered a gold standard for the
treatment of BD.
7. Future directions
Cognitive enhancement strategies in BD are still underdeve-
loped and clearly insufﬁcient. Use of medications aiming to reduce
oxidative stress, modulators of glutamatergic and dopaminergic
neurotransmission, neurotrophic factors and neuropeptides
should be evaluated as potential treatment opportunities. Psycho-
social interventions potentially including neuroregenerative inter-
ventions such as cognitive remediation, physical exercise, coping
abilities and other targets should also be developed in order to
revert the cycle of AL and its dramatic correlates.
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2.1.6. Predictors of recurrence to a specific episode: focus on 
Predominant Polarity 
Emerging evidence suggests that the polarity of episodes over the 
course of bipolar disorder, as well as the polarity of initial or 
index episode may be among the strongest predictors of 
recurrence to a specific episode (Vieta et al.,2009; Calabrese et 
al., 2004). Ever since late ‘70s an attempt was made to classify 
bipolar patients according to predominance of episode polarity, 
when patients were divided into “predominantly manic”, 
“predominantly depressed” and “nuclear” types (Angst, 1978). 
“Manic-prone” vs. “depressive-prone” patients were first 
analyzed in a clinical trial by Quitkin et al. (1986), and later in a 
community sample (Osher et al., 2000), while the first large 
sample was studied in STEP-BD project (Perlis et al., 1995). 
The concept of “predominant polarity” was operationalized and 
validated by Colom et al. (2006). 
A large body of evidence suggests that the predominance of 
polarity in bipolar disorder, defined as at least twice as many 
episodes of one pole of the disorder over the other, is a valid 
prognostic parameter with important clinical and therapeutic 
implications (Colom et al., 2006; Rosa et al., 2008; Vieta et al., 
 
 
2009). According to Colom et al., 2006, about one half of bipolar 
patients qualify for a specific predominant polarity. In European 
and American populations 50–60% of patients present 
predominant depressive polarity and about 40% have 
predominantly manic polarity (Tohen et al., 2009). Only in Israel, 
Osher et al. (2000) reported a predominately manic course of 
illness as more common and did not find any gender-related 
differences in type of illness course. 
Predominantly manic and predominantly depressive bipolar 
patients present important clinical differences. Predominantly 
manic patients were reported to have more frequent presence of 
substance misuse, psychotic symptoms, higher hospitalization 
rate and more cognitive impairment  (Colom et al., 2006; 
Martinez-Aran et al., 2007), while patients with predominantly 
depressive polarity present a higher number of suicide attempts, 
seasonal pattern and melancholic features (Goikolea et al., 2007; 
Rosa et al., 2008). Perugi et al. (2000) reported that the 
polarity of episodes over time reflects polarity at onset. Patients 
with depressive onset were reported to have higher levels of rapid 
cycling and a higher rate of suicide attempts, but were 
significantly less likely to develop psychotic symptoms (Perugi et 
 
 
al., 2000).  
Dell’Osso et al. (2002) reported that insight into specific aspects 
of the illness was related to the polarity of mood episode: patients 
with mania showed significantly poorer insight compared with 
those with mixed mania, bipolar depression and unipolar 
depression, which they hypothesized was due to the persistence 
of subsyndromal symptoms in patients remitting from a manic 
episode (Dell’Osso et al., 2002). 
Considering these clinical differences and high prevalence of 
predominant polarity among bipolar patients, it is a factor that 
should be taken into account when implementing maintenance 
therapy of Bipolar Disorder.  
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Rationale: Due to the episodic and chronic nature of bipolar 
disorder (BD), maintenance therapy represents a critical part of 
treatment; however, there is a paucity of studies comparing 
effectiveness of available long-term treatments.  
Objective: The aim of this study is to determine and compare the 
efficacy of pharmacological treatments for maintenance 
treatment of bipolar disorder by means of the number needed to 
treat (NNT) 
Methods: The efficacy of drugs used for maintenance treatment 
of BD, as emerging from the results of randomized controlled 
trials, was assessed using the size effect measure of NNT. 
PubMed searches were conducted on English-language articles 
published until May 2010 using the search terms “bipolar 
disorder,” “mania,” “mixed episode,” or “bipolar depression,” 
cross-referenced with trial characteristic search phrases and 
 
 
generic names of medications. The search was supplemented by 
manually reviewing reference lists from identified publications. 
Results: In 15 studies, aripiprazole, olanzapine, quetiapine, 
risperidone long-acting injection, lithium, lamotrigine, and 
divalproex proved effectiveness in terms of NNTs (≥10% 
advantage over placebo) for prevention of relapse into any mood 
episode. Quetiapine, lithium, risperidone long-acting injection, 
aripiprazole, and olanzapine are effective in manic recurrence 
prevention. Lamotrigine, quetiapine, and lithium present 
significant NNTs for prevention of depressive relapses. 
Conclusions: All of the pharmacological agents assessed were 
effective in the prevention of any kind of mood episode; 
however, different efficacy profiles were found for prevention of 
manic and/or depressive relapses. The comparison of NNT values 
of the available agents may represent a useful tool in clinical 
settings, in order to facilitate implementation of long-term 
pharmacological interventions in patients with BD.  
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Abstract
Rationale Due to the episodic and chronic nature of bipolar
disorder (BD), maintenance therapy represents a critical
part of treatment; however, there is a paucity of studies
comparing effectiveness of available long-term treatments.
Objective The aim of this study is to determine and
compare the efficacy of pharmacological treatments for
maintenance treatment of BD by means of the number
needed to treat (NNT).
Methods The efficacy of drugs used for maintenance
treatment of BD, as emerging from the results of random-
ized controlled trials, was assessed using the size effect
measure of NNT. PubMed searches were conducted on
English-language articles published until May 2010 using
the search terms “bipolar disorder,” “mania,” “mixed
episode,” or “bipolar depression,” cross-referenced with
trial characteristic search phrases and generic names of
medications. The search was supplemented by manually
reviewing reference lists from identified publications.
Results In 15 studies, aripiprazole, olanzapine, quetiapine,
risperidone long-acting injection, lithium, lamotrigine, and
divalproex proved effectiveness in terms of NNTs (≥10%
advantage over placebo) for prevention of relapse into any
mood episode. Quetiapine, lithium, risperidone long-acting
injection, aripiprazole, and olanzapine are effective in
manic recurrence prevention. Lamotrigine, quetiapine, and
lithium present significant NNTs for prevention of depres-
sive relapses.
Conclusions All of the pharmacological agents assessed
were effective in the prevention of any kind of mood
episode; however, different efficacy profiles were found for
prevention of manic and/or depressive relapses. The
comparison of NNT values of the available agents may
represent a useful tool in clinical settings, in order to
facilitate implementation of long-term pharmacological
interventions in patients with BD.
Keywords Bipolar disorder . NNT. Treatment efficacy .
Maintenance treatment
Introduction
The ongoing research on bipolar disorder (BD) has
highlighted its pervasive and debilitating nature, character-
ized by lifelong recurrent episodes and residual intra-
episodic symptomatology (Keck et al. 2007). Recurrence
rates can reach up to 49% within 2 years of recovery from
an initial episode (Perlis et al. 2006), with the polarity of
the index episode which tends to predict the polarity of
relapse and the risk of recurrence that increments with the
number of mood episodes (Calabrese et al. 2004).
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Management of BD after acute treatment of mood episodes
entails first continuation therapy aiming to prevent relapses,
followed by maintenance therapy focusing on prevention of
recurrences (Calabrese et al. 2006). The maintenance
treatment of BD continues to represent a major clinical
issue. The current first-line treatment strategies for long-term
treatment of bipolar disorder are represented by lithium,
lamotrigine, valproate, olanzapine, quetiapine in monother-
apy and as adjunctive therapy, aripiprazole for the prevention
of manic events, risperidone long-acting injection mono-
therapy and as adjunctive therapy, and adjunctive ziprasi-
done for the prevention of mood events (Yatham et al. 2009).
Monotherapy trials against placebo remain the gold
standard design for determining efficacy in BD (Goodwin et
al. 2008). A recommended tool for reporting results of
clinical trials for bipolar disorder is represented by the
number needed to treat (NNT) analysis (Martinez-Aran et al.
2008). NNT summarizes the effect of treatment in terms of
the number of patients a clinician needs to treat with a
particular therapy to expect to prevent one adverse event.
NNT is a measure of effect size, and calculation of the NNT
can quantify the clinical relevance of a statistically signifi-
cant study result (Citrome 2008). Although NNT has been
described as “the least misleading and most clinically useful
measure of treatment effectiveness” (Gray 2004), it is
considered likely to help translate efficacy-driven clinical
data to information that will more readily guide clinicians on
the benefits of specific interventions in BD (Martinez-Aran
et al. 2008). As a matter of fact, most up-to-date clinical
trials in bipolar disorder have not included NNT analyses.
The aim of the present study was to evaluate and
compare the effects of the pharmacological treatments used
for the long-term management of bipolar disorder by the
means of NNT.
Methods
We systematically reviewed randomized controlled trials
(RCTs) of medications used for the treatment of any phase
of BD. A comprehensive PubMed search of all English-
language articles published up to April 2010 was per-
formed. Terms “bipolar disorder,” “mania,” “mixed epi-
sode,” or “bipolar depression” were cross-referenced with
trial characteristics search phrases and generic names of
medications used for maintenance treatment of BD. The
search was supplemented by manually reviewing reference
lists from the identified publications.
Included RCTs assessed the effectiveness of drugs in the
treatment of BD compared to placebo with a minimal
duration of 6 months and in patients aged over 18.
Exclusion criteria were a small sample size (meaning
median sample inferior to 16.5 subjects in each group as
suggested by Richy et al. 2004), a study sample not
exclusively composed of bipolar patients, the use of rating
scales not validated in patients with bipolar disorder, and an
absence of a placebo control group.
NNT for prevention of relapse into any episode, mania,
and depression for the drugs used for long-term manage-
ment of BD compared to placebo were calculated from the
reports of all the studies that fulfilled the inclusion criteria.
Statistical methods
NNT can be expressed as the reciprocal of the absolute risk
reduction, and is calculated by taking the reciprocals of the
differences between the rates of the outcomes for two
interventions, and rounding upwards to the next whole
number. Only NNTs <10 are considered clinically mean-
ingful. Lower NNTs reflect larger clinical difference
between the comparisons. NNTs of 3, 4 and 9,
corresponding to values of Cohen’s d of 0.8, 0.5 and 0.2,
represent “large,” “medium,” and “small” effect sizes
(Kraemer and Kupfer 2006; Cook and Sackett 1995).
In addition, a 95% confidence interval (CI) for the NNT
was calculated, constructed by inverting and exchanging
the limits of a 95% CI for the absolute risk reduction (Cook
and Sackett 1995). When the treatment effect is significant
at the 5% level, the 95% CI for the absolute risk reduction
will not include zero, and thus the 95% CI for the NNT will
not include infinity (Altman 1998).
Two competing methods have been proposed in order to
calculate NNT from results of systematic reviews; one
method involves calculating the NNT from meta-analytical
estimates, the other by treating the data as if it all arose
from a single trial. Altman and Deeks (2002) found the
“treat-as-one-trial” method to be susceptible to bias when
there were imbalances between groups within one or more
trials in the meta-analysis (Simpson’s paradox). In this
paper, we have followed their suggestion not to use the
treat-as-one-trial method of calculating NNTs, thus, when
more RCTs regarding a single agent were available, we
reported NNTs for data reported in each trial separately.
We have proceeded to calculate NNTs for the prevention
of any kind of recurrences, followed by NNTs of manic and
depressive episodes for each treatment assessed, as reported
in the original studies.
Results
Included studies
Fifteen out of 67 available studies have met the inclusion
criteria. Patient characteristics and primary outcomes of
the selected studies have been reported in the original
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publications. All studies included an acute treatment
phase, followed by a double-blind, relapse-prevention
(maintenance) treatment phase. Some of the RCTs used a
three-arm design thus could be used to make two
comparisons each. In some cases, two or more articles/
references provide data for the same RCT.
Table 1 illustrates the available studies comparing
therapeutic agents for maintenance therapy of bipolar mood
episodes commonly prescribed for the long-term treatment
of bipolar disorder with placebo.
Table 2 shows rates of relapse into any mood episode,
mania, and depression as published in the original articles.
Table 3 provides the NNT versus placebo for recurrence
prevention for any mood episode and for manic and
depressive episodes specifically for several treatments of
interest.
Pharmacological agents used in maintenance treatment
of bipolar disorder
Aripiprazole
The only relapse-prevention study conducted on aripipra-
zole in BD I patients showed that aripiprazole 15–30 mg/
day was significantly superior to placebo in prevention of
relapse into any mood episode during a 100-week-long
double-blind treatment, with an NNT value of 6 (Keck et al.
2007).Aripiprazole was significantly superior to placebo in
preventing relapse to mania, which translates into an NNT
of 7. No difference in prevention of depressive relapses was
noted between aripiprazole and placebo.
Given that efficacy was shown for the prevention of any
mood episode and for mania in particular, aripiprazole
represents a first-line option for treatment and prevention of
mania in maintenance treatment of bipolar disorder.
Olanzapine
Two placebo-controlled studies with maintenance treatment
phases of 12 and 18 months were available for NNT
analyses (Tohen et al. 2006, 2004).
When comparing olanzapine to placebo over 12 months
(Tohen et al. 2006), the NNT was three for prevention of
symptomatic relapse to any mood episode, indicating a
large clinical maintenance effect size difference between
olanzapine and placebo. When olanzapine plus lithium or
valproate was compared with placebo plus lithium or
valproate over an 18-month period, the NNT for the
prevention of any episode was not significant.
Furthermore, olanzapine showed a significant difference in
the risk of relapse into manic episodes over placebo for up to
12 months (Tohen et al. 2006), corresponding to an NNT of
5; however, no significant differences emerged from the
study comparing olanzapine combined with lithium or
valproate with placebo combined with lithium or valproate
over 18 months (Tohen et al. 2004). Olanzapine in
monotherapy or combined with lithium or divalproex was
not significantly superior to placebo in preventing relapse
into depressive episodes (Tohen et al. 2006).
Overall, olanzapine in monotherapy has proven efficacy
for prevention of any mood episode as well as manic
episodes. Although olanzapine combined with lithium or
valproate (Tohen et al. 2004) had an NNT of six for
prevention of any mood episode, as well as of depression, it
cannot be considered significant since CI crossed infinity.
Quetiapine
Three placebo-controlled randomized double-blind studies
assessed the efficacy of quetiapine in long-term treatment
of BD I (Vieta et al. 2008a, b; Suppes et al. 2009; Weisler et
al. 2008).
Two studies (Vieta et al. 2008a; Suppes et al. 2009)
assessing effectiveness of quetiapine as add-on therapy
during continuation treatment for up to 104 weeks demon-
strated that quetiapine in combination with lithium or
divalproex was significantly more effective than lithium
or divalproex alone in the prevention of mood episodes,
which translates into an NNT of 4. In a recent study by
Weisler et al. (2008), evaluating quetiapine as monotherapy
for up to 104 weeks, quetiapine was found effective in the
prevention of any mood episode, with an NNT of 3.
Quetiapine in combination with lithium or divalproex
was significantly more effective than the placebo in
combination with lithium or divalproex in preventing
recurrence of mania, assuming an NNT value of seven in
the study by Vieta et al. (2008a) and nine in the study by
Suppes et al. (2009). Likewise, quetiapine in monotherapy
(Weisler et al. 2008) was significantly more effective than
placebo in the prevention of mania, with an NNT of 3.
NNTs were significant for quetiapine plus lithium or
divalproex in preventing depressive relapses in the two
studies evaluating quetiapine as adjunctive therapy, with
values of 7 (Vieta et al. 2008a) and 6 (Suppes et al. 2009).
Quetiapine in monotherapy assumed an NNT value of 4 in
the prevention of depressive episodes (Weisler et al. 2008).
Taken together, these data indicate that quetiapine alone
and combined with lithium or valproate was effective in
preventing any mood episode and has a similar efficacy for
prevention of mania and depression.
Risperidone long-acting injection
Although the long-term efficacy of oral risperidone has not
yet been assessed (Yatham et al. 2009), two RCTs have
examined the efficacy of risperidone long-acting injection
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Table 1 Characteristics of included randomized controlled studies
Trial (in order of
appearance in text)
Patient inclusion criteria (maintenance phase) Duration (weeks) Number randomized Dosage (mg/day) or plasma
levels/mean dosage
Keck et al. (2007) Bipolar I≥18 years 100 ARI=78 ARI, 15–30 mg/day; mean,
23.8 mg/dayYMRS≤10 PLA=83
MADRS≤13
No hospitalization in previous 3 months
Tohen et al. (2006) Bipolar I 48 OLZ=225 OLZ, 5–20 mg/day
≥18 years PLA=136
YMRS≤12
HAM-D≤8
Two prior mixed or manic episodes
in the past 6 years
Tohen et al. (2004) Bipolar I 72 LI/VPA+PLA=48 OLZ, 5–20 mg/day; mean,
12.5 mg/day
18–70 years LI/VPA+OLZ=51 LI, 0.66–0.86 mEq/L
YMRS≤12 VPA, 60.1–73.8 μg/mL
HRSD-21≤8
Vieta et al. (2008a) Bipolar I 104 QUE+LI/VPA=336 QUE, 400–800 mg/day; mean,
497 mg/day
≥18 years PLA+LI/VPA=367 LI, 0.5–1.2 mEq/L
YMRS≤12 VPA, 50–125 μg/mL
HAM-D≤12
Suppes et al. (2009) Bipolar I 104 QUE+LI/VPA=310 QUE, 400–800 mg/day; mean,
519 mg/day
≥18 years PLA+LI/VPA=313 LI, 0.5–1.2 mEq/L
YMRS≤10
MADRS≤13 Mean, 0.71–0.74 mEq/L
VPA, 50-125 μg/mL
Mean, 68.91–71.38 μg/mL
Weisler et al. (2008) Bipolar I 104 QUE=404 QUE, 300–800 mg/day
≥18 years LI=364 Li, 0.6–1.2 mEq/L
YMRS≤12 PLA=404
MADRS≤12 Acute current or recent
(past 26 weeks) manic, depressive, or
mixed index episode treated with QUE
Quiroz et al. (2010) Bipolar I 96 RLAI=140 RIS, 12.5–50 mg i.m.; mean,
25 mg18–65 years PLA=136
Recent manic/mixed episode or stable
patients with≥1 mood episode in
past 4 months
Macfadden et al. (2009) Bipolar I 52 RLAI+TAU=65 RLAT, 25–50 mg/2 weeks
18–70 years PLA+TAU=59
≥4 episodes in the past year
Bowden et al. (2010) Bipolar I 24 ZIP+LI/VPA=127 ZIP, 80–160 mg/day
≥18 years PLA+LI/VPA=113 LI, 0.6–1.2 mEq/L
Current or recent manic/mixed episode Mean, 0.7–0.9 mEq/L
VPA, 50–125 μg/mL; mean,
67.4–72.8
Bowden et al. (2003) Bipolar I 76 LAM=59 LAM, 100–400 mg/day
≥18 years LI=46 LI, 0.8–1.1 mEq/L
Current or recent (hypo)mania≥1 additional
(hypo)manic and 1 depressive episode
in the past 3 years
PLA=70
Calabrese et al. (2003) Bipolar I 72 LAM=221 LAM, 50–400 mg/day; mean,
200 mg/day
≥18 years LI=121 LI, 0.8–1.1 mEq/L; mean,
0.8±0.3 mEq/LCurrent or recent MDE PLA=121
≥1 additional (hypo)manic and 1 depressive
episode in the past 3 years
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(RLAI) for maintenance treatment in BD (Quiroz et al.
2010; Macfadden et al. 2009).
A recent study examined the long-term efficacy of RLAI
(Quiroz et al. 2010) in patients with recent manic or mixed
episode followed up for up to 24 months.
RLAI monotherapy was shown to be superior to placebo
in preventing any mood episode with an NNT of 4. A study
conducted by Macfadden et al. (2009) assessed RLAI as an
adjunct to treatment as usual for 52 weeks in 139 patients
who had frequently relapsing BD. Significantly fewer
patients in the adjunctive RLAI group relapsed into any
mood episode compared with those in the placebo group,
corresponding to an NNT of 5.
When comparing RLAI to placebo over 24 months
(Quiroz et al. 2010), NNT was four for the prevention of
manic recurrences and eight in the 52-week follow-up trial
conducted by Macfadden et al. (2009).
NNT was not significant for the prevention of depressive
episodes in either available study (Quiroz et al. 2010;
Macfadden et al. 2009).
Overall, RLAI has proven efficacy for the prevention of
any kind of mood episodes, as well as for the prevention of
mania while it did not result effective for the prevention of
depressive episodes.
Ziprasidone
The efficacy of adjunctive ziprasidone for maintenance
treatment of bipolar mania was demonstrated in a recent
6-month-long RCT in 239 patients with BD I (Bowden et
al. 2010). When comparing ziprasidone to placebo, NNT
assumed the value of 8 for the prevention of any mood
episode while it was not significant for the prevention of
manic or depressive episodes (Fig. 1).
Lamotrigine
Two RCTs compared lamotrigine, lithium, and placebo in
maintenance treatment of recently manic (Bowden et al. 2003)
and depressed (Calabrese et al. 2003) bipolar I patients.
Since the studies were prospectively designed for combined
analyses, a pooled analysis from the two abovementioned
studies (Goodwin et al. 2004), allowing greater power with
respect to the original studies, was available for NNT
analysis and therefore included in the present paper. An
additional double-blind, placebo-controlled study examining
lamotrigine as maintenance monotherapy for rapid-cycling
bipolar patients was available for NNT analysis exclusively
for prevention of any mood episode (Calabrese et al. 2000).
Table 1 (continued)
Trial (in order of
appearance in text)
Patient inclusion criteria (maintenance phase) Duration (weeks) Number randomized Dosage (mg/day) or plasma
levels/mean dosage
Calabrese et al. (2000) Bipolar I and II, rapid 26 LAM=90 LAM, 100–300 mg/day
cycling PLA=87
≥18 years
≤14 HAM-D
≤12 MRS
<3 on item 3 HAM-D stable
for 4 weeks
Prien et al. (1973) Manic–depressive, manic type 24a LI=101 LI, 0.5–1.4 mEq/L
PLA=104
Bowden et al. (2000) Bipolar I 52 VPA=187 VPA, 71–125 μg/mL
18–70 years LI=90 LI, 0.8–1.2 mmol/L
Manic episode≤3 months
before randomization
PLA=92
MRS≤11
DSS≤13
GAS>60, no serious suicidal risk
Vieta et al. (2008b) Bipolar I or II 52 OXC+LI=26 OXC, 1,200 mg/day
≥18 years PLA+LI=29 LI, 0.6 mEq/L
YMRS≤12
MADRS≤20
No acute phases in 6 months
PLA placebo, ARI aripiprazole, OLZ olanzapine, LI lithium, VPA valproate, QUE quetiapine, TAU treatment as usual, ZIP ziprasidone, LAM
lamotrigine, OXC oxcarbazepine
aNNT analyses refer to 12-month period
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Table 2 Relapse rates reported in randomized controlled trials of pharmacological agents used for maintenance treatment of bipolar disorder
Any episode n (%) Mania n (%) Depression n (%)
PCB relapse Drug relapse PCB relapse Drug relapse Placebo relapse Drug relapse
Aripiprazole 43/83 25/77 23/83 9/77 13/83 11/77
(Keck et al. 2007) 51.81 32.47 27.71 11.69 15.66 14.28
Olanzapine 109/136 105/225 44/136 27/225 53/136 68/225
(Tohen et al. 2006) 80.14 46.66 32.35 12 38.97 30.22
Olanzapine combined with 21/38 11/30 11/38 6/30 15/38 7/30
lithium/divalproex
(Tohen et al. 2004)a
55.26 36.66 28.94 20 39.47 23.33
Quetiapine combined with 180/367 62/336 96/367 36/336 84/367 26/336
lithium/divalproex
(Vieta et al. 2008a, b)
49.04 18.53 26.16 10.71 22.89 7.74
Quetiapine combined with 163/313 63/310 61/313 22/310 102/313 41/310
lithium/divalproex
(Suppes et al. 2009)
52.08 20.32 19.49 19.49 32.59 13.23
Quetiapine 343/404 162/404 291/404 121/404 186/404 65/404
(Weisler et al. 2008) 84.90 40.10 72.03 29.95 46.04 16.09
Risperidone LAI 76/135 42/140 62/135 22/140 41/135 14/135
(Quiroz et al. 2010) 56.29 30 45.93 15.71 10.37 14.29
Risperidone LAI+ 27/59 15/65 12/59 5/65 11/59 8/65
treatment as usual
(Macfadden et al. 2009)
45.76 23.08 20.34 7.69 18.64 12.31
Ziprasidone combined with 36/111 25/127 14/111 7/127 16/111 16/127
lithium/divalproex
(Bowden et al. 2010)
32.43 19.69 12.61 5.51 14.41 12.60
Lamotrigine 49/70 28/59 22/70 16/59 21/70 8/59
(Bowden et al. 2003) 70 47.46 31.43 27.12 30 13.56
Lamotrigine 66/119 115/215 19/119 38/215 47/119 77/215
(Calabrese et al. 2003) 55.46 53.49 15.97 17.67 39.50 35.81
Lamotrigine 64/87 53/90 N.A. N.A. N.A. N.A.
(Calabrese et al. 2000) 73.56 58.89
Lamotrigine 115/191 143/280 47/191 58/280 68/191 85/280
(Goodwin et al. 2004) 60.21 51.07 24.61 20.71 35.60 30.36
Lithium 71/104 36/101 53/104 23/101 14/104 9/101
(Prien et al. 1973) 68.27 35.64 50.96 22.77 13.46 8.91
Lithium 115/191 74/167 47/191 18/167 68/191 56/167
(Goodwin et al. 2004) 60.21 44.31 24.61 10.78 35.60 33.53
Lithium 49/70 18/46 22/70 6/46 21/70 10/46
(Bowden et al. 2003) 70 39.13 31.43 13.04 30 21.74
Lithium 66/119 56/120 19/119 10/120 47/119 46/120
(Calabrese et al. 2003) 55.16 46.67 15.97 8.93 33.50 38.33
Lithium 36/94 28/91 21/94 19/91 15/94 9/91
(Bowden et al. 2000) 38.30 30.77 22.34 20.80 9.89 15.96
Lithium 343/404 149/364 291/404 102/364 186/404 66/364
(Weisler et al. 2008) 84.90 40.93 72.03 28.02 46.04 18.13
Valproate 36/94 45/187 21/94 33/187 15/94 12/187
(Bowden et al. 2000) 38.29 24.06 22.34 17.65 15.96 6.42
Oxcarbazepine combined with lithium 17/29 10/26 8/29 4/26 9/29 3/26
(Vieta et al. 2008a, b) 58.62 38.46 27.58 15.38 31.03 11.54
a Data referring to symptomatic relapse
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When compared to placebo, lamotrigine in monotherapy
was found to be effective in the prevention of any mood
episode in recently manic patients (Bowden et al. 2003)
with an NNT of 5, and showed no significant difference in
recently depressed patients (Calabrese et al. 2003). Data
emerging from the pooled analyses (Goodwin et al. 2004)
evidenced an NNT of 11 for prevention of any mood
episode.
Lamotrigine was not significantly superior to placebo in
the prevention of mania in any of the abovementioned
studies (Bowden et al. 2003; Calabrese et al. 2003;
Goodwin et al. 2004).
Lamotrigine was found to be superior to placebo in
preventing depressive episodes in recently manic patients
(Bowden et al. 2003), with an NNT value of 7. In contrast,
lamotrigine was not significantly superior to placebo in the
prevention of depressive episode neither in recently
depressed patients (Calabrese et al. 2003) nor in the pooled
analyses (Goodwin et al. 2004).
Lamotrigine in monotherapy was found effective in
preventing any kind of mood episode. Its effectiveness was
also demonstrated for the prevention of depressive episodes
in recently manic patients.
Lithium
Although lithium has been considered to be the cornerstone
of bipolar disorder maintenance treatment for many years,
since the mid 1970s until 2000, no RCTs assessing lithium
efficacy were published (Coryell 2009).
Only one of the studies on lithium conducted in the
1970s satisfied the inclusion criteria. A double-blind trial
by Prien et al. (1973) assessed the efficacy of lithium over a
2-year period. NNT analyses relevant to a 1-year period
evidenced effectiveness of lithium in preventing any mood
episode, translating to an NNT of 4.
Four recent double-blind studies examined the efficacy
of lithium as a maintenance treatment (Bowden et al. 2000,
Table 3 NNT values for recurrence prevention of pharmacological agents used for maintenance treatment of bipolar disorder compared to placebo
NNT any episode (95% CI) NNT mania (95% CI) NNT depression (95% CI)
Aripiprazole (Keck et al. 2007) 6 (2.9–23) 7 (3.6, 24.9) 50.0 (7.7, infinity)
Olanzapine (Tohen et al. 2006) 3 (2.3, 4.2) 5 (3.4, 8.8) 12 (5.3, infinity)
Olanzapine combined with Lithium/Divalproex
(Tohen et al. 2004)a
6 (2.4, infinity) 12 (3.4, infinity) 6 (2.6, infinity)
Quetiapine combined with Lithium/Divalproex
(Vieta et al. 2008a, b)
4 (2.7–4.2) 7 (4.8, 10.1) 7 (4.9, 10.0)
Quetiapine combined with Lithium/Divalproex
(Suppes et al. 2009)
4 (2.6, 4.1) 9 (5.7, 14.0) 6 (3.9, 7.7)
Quetiapine (Weisler et al. 2008) 3 (2, 2.6) 3 (2, 2.8) 4 (2.8, 4.2)
Risperidone LAI (Quiroz et al. 2010) 4 (2.4, 5.6) 4 (2.5, 5.0) 26 (8.6, infinity)
Risperidone LAI+Treatment as Usual
(Macfadden et al. 2009)
5 (2.6, 15.7) 8 (4.0, 198.7) 16 (5.2, infinity)
Ziprasidone combined with Lithium/Divalproex
(Bowden et al. 2010)
8 (4.2, 61.5) 15 (6.9, infinity) 56 (9.5, infinity)
Lamotrigine (Bowden et al. 2003) 5 (2.6, 17.0) 24 (5.0, infinity) 7 (3.3, 38.5)
Lamotrigine (Calabrese et al. 2003) 51 (7.6, infinity) 59 (10.0, infinity) 28 (6.9, infinity)
Lamotrigine (Calabrese et al. 2003) 7 (3.5, 108.8) N.A. N.A.
Lamotrigine (Goodwin et al. 2004) 11 (5.5, 1764.7) 26 (8.6, infinity) 20 (7.2, infinity)
Lithium (Prien et al. 1973) 4 (2.2, 5.1) 4 (2.5, 6.4) 22 (7.6, infinity)
Lithium (Goodwin et al. 2004) 7 (3.8, 17.7) 8 (4.6, 16.3) 49 (8.4, infinity)
Lithium (Bowden et al. 2003) 4 (2.3, 20.5) 6 (3, 26.4) 13 (4.1, infinity)
Lithium (Calabrese et al. 2003) 12 (4.7, infinity) 14 (6.3, infinity) 86 (7.4, infinity)
Lithium (Bowden et al. 2000) 14 (4.7, infinity) 69 (7.5, infinity) 17 (6.4, infinity)
Lithium (Weisler et al. 2008) 3 (2, 2.6) 3 (2.2, 2.7) 4 (2.8, 4.4)
Valproate (Bowden et al. 2000) 7 (3.9, 37.7) 22 (6.8, infinity) 11 (5.6, 74.3)
Oxcarbazepine combined with Lithium
(Vieta et al. 2008a, b)
5 (2.2, infinity) 9 (3.0, infinity) 6 (2.5, infinity)
Significant NNTs are in bold numbers
a Data referring to symptomatic relapse
N.A.= Not available
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2003; Calabrese et al. 2003; Weisler et al. 2008). In the
study by Bowden et al. (2000), lithium was not signifi-
cantly superior to placebo in preventing mood episodes
over 1 year in a cohort of 372 patients with BD I. In two
studies (Bowden et al. 2003; Calabrese et al. 2003), both
previously described, lithium was studied as an active
comparator medication compared to a lamotrigine-enriched
sample of patients with BD I. In the study by Bowden et al.
(2003), lithium was found to be significantly more effective
than placebo in preventing any mood episode, with an NNT
of 4 while in recently depressed BD I patients the difference
was not significant. In a pooled analysis of the two studies
(Goodwin et al. 2004), lithium was significantly more
effective than placebo in preventing any mood episode,
with an NNT value of 7. In a recent RCT conducted by
Weisler et al. (2009) where bipolar I patients were followed
up for up to 104 weeks, lithium, assessed as active
comparator, has proven its effectiveness in preventing any
kind of mood episode, with an NNT of 3.
Regarding the prevention of manic episodes, in the study
by Prien et al. (1973) lithium was effective in the
prevention of manic episodes, with an NNT of 4. Lithium
was also found to be significantly more effective than
placebo in preventing mania in recently manic patients
(Bowden et al. 2003), with an NNT of 2, as well as in
pooled analyses of the two studies (Goodwin et al. 2004).
Likewise, in the study by Weisler et al. (2009), lithium
assumed an NNT value of three for mania prevention;
however, lithium was not significantly superior to placebo
in preventing manic recurrences in the remaining two
studies (Bowden et al. 2000; Calabrese et al. 2003).
Lithium was found significantly superior to placebo in
preventing depressive episodes, with an NNT of 4, only in
the study by Weisler et al. (2009) while it resulted not
significantly superior to placebo in preventing depression in
any other of the abovementioned studies (Prien et al. 1973;
Bowden et al. 2000; Bowden et al. 2003; Calabrese et al.
2003; Goodwin et al. 2004).
In conclusion, since the efficacy of lithium was largely
demonstrated for the prevention of any mood episode, in
particular for mania, lithium continues to represent a first-
line maintenance treatment for bipolar disorder for the
treatment and prevention of mania.
Valproate
Only one study assessing valproate in maintenance treat-
ment of bipolar disorder was available for NNT analyses. A
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Fig. 1 Second-generation
antipsychotics in maintenance
treatment of bipolar disorder
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randomized, double-blind, parallel-group multicenter study
of treatment outcomes was conducted over a 52-week
maintenance period (Bowden et al. 2000). Patients with a
previous manic episode were randomized to maintenance
treatment with divalproex, lithium, or placebo. Although
the authors concluded that the treatment arms did not differ
significantly on time to recurrence of any mood episode
during maintenance therapy, the NNT for prevention of any
mood episode was 7; however, valproate did not result
superior to placebo in preventing neither manic nor
depressive episodes.
Oxcarbazepine
One RCT assessed the efficacy of oxcarbazepine compared
to placebo as adjuncts to ongoing treatment with lithium in
55 patients with BD I and BD II for a period of 52 weeks
(Vieta et al. 2008b). The results evidenced a lower risk of
recurrence to any mood episode with oxcarbazepine,
corresponding to an NNT of 5, but this difference was not
significant since the CI crossed infinity. The same was true
for the prevention of manic and depressive episodes, with
NNT values of 9 and 6, respectively, neither statistically
significant (Fig. 2).
Discussion
Due to the episodic and chronic nature of the illness,
maintenance therapy is a critical part of treatment for
bipolar disorder. The ultimate goal of treatment is the
prevention of episode recurrence through the long-term
management of the symptoms (Thase 2008).
NNT is a useful and meaningful concept for practicing
clinicians which may help to translate the results of
randomized controlled clinical trials to evidence-based
medicine (Martinez-Aran et al. 2008). Nonetheless, most
of the published studies have not reported NNT values for
assessed medicaments. To the best of our knowledge this is
the first paper providing NNTs for all available placebo-
controlled trials for agents used in long-term treatment of
BD.
NNT analysis evidenced differences in efficacy profiles
among various agents used for the maintenance treatment
for bipolar disorder. In general, our findings are in
agreement with the recommendations of recent guidelines
for the maintenance therapy of bipolar disorder (Yatham et
al. 2009). Aripiprazole, olanzapine, quetiapine, risperidone
LAI, ziprasidone, lithium, lamotrigine, and valproate have
single-digit NNTs and are significantly effective for the
0
1
2
3
4
5
6
7
8
9
10
NNT
L
A
M
 (
B
o
w
d
en
, 
2
0
0
3
)
L
A
M
 (
C
al
ab
re
se
, 
2
0
0
0
)
L
I 
(P
ri
en
, 
1
9
7
3
)
L
I 
(G
o
o
d
w
in
, 
2
0
0
4
)
L
I 
( 
B
o
w
d
en
,2
0
0
3
)
L
I 
(W
ei
sl
er
, 
2
0
0
9
)
 V
P
A
 (
 B
o
w
d
en
, 
2
0
0
0
)
MS
Any episode Mania Depression
SGA= second generation antipsychotic, MS= mood stabilizer, PLA=placebo, LI=lithium, VPA= valproate,
LAM=lamotrigine
Fig. 2 Mood stabilizers in
maintenance treatment of
bipolar disorder (significant
NNTs) SGA second-generation
antipsychotic, MS mood
stabilizer, PLA placebo, LI
lithium, VPA valproate, LAM
lamotrigine
Psychopharmacology (2011) 213:657–667 665
prevention of any mood episode, but show substantial
differences as to their ability to prevent mania and
depression separately. Among the agents assessed, the only
exception is given by oxcarbazepine combined with lithium
that had a significant single-digit NNT for prevention of
any episode, mania, and depression, but CI did not result
significant, probably for the lack of power due to the
relatively small sample size.
The NNT analyses confirmed the efficacy of quetiapine
(in monotherapy and combined with mood stabilizer),
lithium, risperidone LAI, aripiprazole, and olanzapine in
preventing manic recurrences. Lamotrigine, lithium, and
quetiapine alone and combined with lithium/valproate
presented significant NNTs for the prevention of depressive
relapses. The data emerging from our analysis provide utter
evidence that the treatments assessed differentiated in terms
of whether they primarily prevent mania or depression or
have bidirectional effects. The clinical relevance of the
directional efficacy of the various medications is height-
ened in the context of predominant polarity, a parameter
correlated with treatment response and outcome of later
acute episodes (Vieta et al. 2009; Colom et al. 2006);
nevertheless, placebo-controlled randomized clinical trials
assessing long-term effectiveness of mood stabilizers and
antipsychotics are surprisingly sparse, and important ques-
tions remain unanswered.
In order to present the most complete data available, we
have included both RCTs assessing drugs in monotherapy
as well as combined with mood stabilizers such as lithium
and valproate. The studies were not completely homoge-
neous with respect to clinical characteristics of the sample
(rapid-cycling course, manic/mixed states or depression,
refractory patients or unbiased samples), sample size, and
rates of study completion, which may compromise to some
extent the generalizability of reported NNTs.
In the interest of brevity, we have not addressed the
number needed to harm analysis, although medication
selection is based on tolerability as well as effectiveness.
NNTs for the prevention of mixed episodes were omitted
since most available RCTs have not proceeded to such
assessment and the number of events in the trials that did
look at it was extremely small.
An apparent paradox emerges from NNT values
analyses. Namely, it may seem surprising that NNT for
the prevention of any mood episode is often smaller than
NNT for the prevention of manic or depressive relapses
separately; however, one should bear in mind that the
included studies were designed to assess efficacy in
terms of prevention of any mood episode as primary aim.
NNT for prevention of any mood episode reflects the
sum of effects that a drug has upon any episode, manic,
depressive, mixed, or unknown type, conferring it more
power than any episode taken singularly; thus a drug
may perform better overall in comparison to its best
effect upon a single episode.
Successful long-term management often appears to
require combination treatment, and although assessing
combined treatments went beyond the aims of our study,
lack of such trials, e.g., lamotrigine as add-on treatment,
should be an object of future research. Further studies are
needed in order to address the long-term effectiveness of
agents such as carbamazepine, oxcarbazepine, and val-
proate. Some antipsychotics, such as amisulpride, asena-
pine, or paliperidone have not been assessed in long-term
placebo-controlled studies.
Conclusions
The present review of clinical effectiveness by the means of
NNT comparison aimed to investigate all pharmacological
treatments approved as maintenance therapy in BD. Most
of the pharmacological agents assessed were effective in the
prevention of any kind of mood episode; however, different
efficacy profiles were found for the prevention of manic
and/or depressive relapses. The comparison of NNT values
of the available medicaments may represent a useful
adjuvant in clinical settings, in order to facilitate imple-
mentation of long-term pharmacological interventions in
patients with BD.
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Abstract
Over one half of bipolar patients have been reported to be more prone to either depressive or
manic relapses. This study aimed to define profiles of drugs used for maintenance treatment
of bipolar disorder (BD) by the means of Polarity Index. Polarity Index is a new metric indicating
the relative antimanic versus antidepressive preventive efficacy of drugs. Polarity Index was re-
trieved by calculating Number Needed to Treat (NNT) for prevention of depression and NNT for
prevention of mania ratio, as emerging from the results of randomized placebo-controlled trials.
Included trials were randomized and double blind, with a minimal duration of 24 weeks, asses-
sing effectiveness of a mood stabilizer or antipsychotic drug alone or in combination with a
mood stabilizing agent versus a placebo comparator in BD maintenance treatment. Polarity
Index value above 1.0 indicates a relative greater antimanic prophylactic efficacy, number
below 1.0 a relative greater antidepressive efficacy. The polarity index for the drugs used in
maintenance therapy for bipolar disorder was 12.09 for risperidone, 4.38 for aripiprazole, 3.91
for ziprasidone, 2.98 for olanzapine, 1.39 for lithium, 1.14 for quetiapine, and 0.40 for lamotri-
gine. Polarity index of valproate and oxcarbazepine may not be reliable due to the failure of
their maintenance trials. The polarity index provides a measure of how much antidepressant
versus antimanic a drug is in bipolar disorder prophylaxis, and may guide the choice of mainte-
nance therapy in bipolar patients.
© 2011 Elsevier B.V. and ECNP. All rights reserved.linic, Villarroel 170, Barcelona
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Ever since late ‘70s an attempt was made to classify bipolar
patients according to predominance of episode polarity
when patients were divided into “predominantly manic”,
“predominantly depressed” and “nuclear” types (Angst,s reserved.
Table 1 Characteristics and reported results of included randomized controlled studies.
Trial characteristics Study results
Drug Trial Patient inclusion criteria (maintenance phase) Duration
(weeks)
Manic relapse Depressive
relapse
PBO
relapse
Drug
relapse
PBO
relapse
Drug
relapse
Aripiprazole Keck et al., 2007 Bipolar I
YMRS ≤10
MADRS ≤13
No hospitalization in previous 3 months
100 23/83
27.71%
9/77
11.69%
13/83
15.66%
11/77
14.28%
Aripiprazole combined
with lithium/divalproex
Marcus et al., 2011 Bipolar I
YMRS ≥16
Curent or recent manic/mixed episode
Inadequate response to lithium or valproate YMRS ≥16 and ≤35%
decrease from baseline at 2 weeks
52 25/169
14.79%
8/168
4.76%
22/169
13.02%
17/168
10.12%
Lamotrigine Bowden et al., 2003 Bipolar I
Current or recent (hypo)mania ≥1 additional (hypo)manic and 1
depressive episode in the past 3 years
76 22/70
31.43%
16/59
27.12%
21/70
30.00%
8/59
13.56%
Lamotrigine Calabrese et al., 2003 Bipolar I
Current or recent MDE
≥1 additional (hypo)manic and 1 depressive episode in the past 3 years
72 19/119
15.97%
38/215
17.67%
47/119
39.50%
77/215
35.81%
Lithium Bowden et al., 2003 Bipolar I
Current or recent
(hypo)mania
≥1 additional (hypo)manic and 1 depressive episode in the past 3 years
76 22/70
31.43%
6/46
13.04%
21/70
30%
10/46
21.74%
Lithium Bowden et al., 2000 Bipolar I
Manic episode ≤3 months before randomization.
MRS ≤11
DSS ≤13
GAS N60,
No serious suicidal
risk
52 21/94
22.34%
19/91
20.88%
15/94
15.96%
9/91
9.89%
Lithium Calabrese et al., 2003 Bipolar I
Current or recent MDE
≥1 additional (hypo)manic and 1 depressive episode in the past 3 years
72 19/119
15.97%
10/120
8.33%
47/119
39.50%
46/120
38.33%
Lithium Prien et al., 1973 Manic-depressive, manic type 24a 53/104
50.96%
23/101
22.77%
14/104
13.46%
9/101
8.91%
Lithium Weisler et al., 2008 Bipolar I
YMRS ≤12
MADRS ≤12
Acute current or recent manic, depressive, or mixed index episode
treated with QUE
104 291/404
72.03%
102/364
28.02%
186/404
46.04%
66/364
18.13%
340
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Olanzapine Tohen et al., 2006 Bipolar I
YMRS ≤12
HAM-D ≤8
2 prior mixed or manic episodes in past 6 years
48 44/136
32.35%
27/225
12%
53/136
38.97%
68/225
30.22%
Olanzapine Vieta et al., accepted
for publication
Bipolar I
≥2 mood episodes in the previous year
52/132
39.39%
19/130
14.61%
23/132
17.42%
12/130
9.23%
Olanzapine combined
with lithium/divalproex
Tohen et al., 2004 Bipolar I
YMRS ≤12
HRSD-21≤8
72 11/38
28.95%
6/30
20%
15/38
39.47%
7/30
23.33%
Oxcarbazepine combined
with lithium
Vieta et al. (2008b) Bipolar I or II
YMRS ≤12
MADRS ≤20
No acute phases in
6 months
52 8/29
27.59%
4/26
15.38%
9/29
31.03%
3/26
11.54%
Quetiapine Weisler et al., 2008 Bipolar I
YMRS ≤12
MADRS ≤12
Acute current or recent manic, depressive, or mixed index episode
treated with QUE
104 291/404
72.03%
121/404
29.95%
186/404
46.04%
65/404
16.09%
Quetiapine combined with
lithium/divalproex
Suppes et al., 2009 Bipolar I
YMRS≤10
MADRS≤13
104 61/313
19.49%
22/310
7.09%
102/313
32.59%
41/310
13.23%
Quetiapine combined with
lithium/divalproex
Vieta et al. (2008a) Bipolar I
YMRS ≤12
HAM-D ≤12
104 96/367
26.16%
36/336
10.71%
84/367
22.89%
26/336
7.74%
Risperidone LAI Quiroz et al., 2010 Bipolar I
Recent manic/mixed episode or stable patients with ≥1 mood
episode in past 4 months
96 62/135
45.93%
22/140
15.71%
14/135
10.37%
20/140
14.29%
Risperidone LAI Vieta et al., accepted
for publication
Bipolar I ≥2 mood episodes in the previous year 52/132
39.39%
26/131
19.84%
23/132
17.42%
25/131
19.08%
Risperidone LAI+
treatment as Usual
Macfadden et al., 2009 Bipolar I ≥4 episodes in the past year 52 12/59
20.34%
5/65
7.69%
11/59
18.64%
8/65
12.31%
Valproate Bowden et al., 2000 Bipolar I
Manic episode ≤3 months before randomization.
MRS ≤11
DSS ≤13
GAS N60,
No suicidal risk
52 21/94
22.34%
33/187
17.65%
15/94
15.96%
12/187
6.42%
Ziprasidone combined
with lithium/divalproex
Bowden et al., 2010 Bipolar I
Curent or recent manic/mixed episode
MRS≥14
24 14/111
12.61%
7/127
5.51%
16/11
14.41%
16/127
12.60%
a NNT analyses refer to 12-month period.
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342 D. Popovic et al.1978). “Manic-prone” vs. “depressive-prone” patients were
first analyzed in a clinical trial by Quitkin et al. (1986), and
later in a community sample (Osher et al., 2000), while the
first large sample was studied in STEP-BD project (Perlis
et al., 1995). The concept of “predominant polarity” was
operationalized and validated by Colom et al. (2006).
Thus, a large body of evidence suggests that the predomi-
nance of polarity in bipolar disorder (BD), defined as at
least twice as many episodes of one pole of the disorder
over the other, is a valid prognostic parameter with impor-
tant clinical and therapeutic implications (Colom et al.,
2006; Rosa et al., 2008; Vieta et al., 2009). According to
Colom et al., 2006, about one half of bipolar patients qual-
ify for a specific predominant polarity. In European and
American populations 50–60% of patients present predomi-
nant depressive polarity and about 40% have predominantly
manic polarity (Tohen et al., 2009). Only in Israel a study
by Osher et al. (2000) detected a predominately manic
course of illness is more common and did not find any
gender-related differences in type of illness course.
Marked clinical differences between predominantly
manic and depressive bipolar patients, namely more fre-
quent presence of substance misuse, psychotic symptoms,
hospitalizations and cognitive impairment among patients
with manic polarity (Colom et al., 2006; Martinez-Aran
et al., 2007) and a higher number of suicide attempts, sea-
sonal pattern and melancholic features in patients with pre-
dominantly depressive polarity (Goikolea et al., 2007; Rosa
et al., 2008), justify the need of a differential treatment ap-
proach according to predominant polarity.
The current first-line treatment strategies for long term
treatment of BD are represented by lithium, lamotrigine,
valproate, olanzapine, quetiapine, aripiprazole, risperidone
LAI (long-acting injectable formulation) and ziprasidone
(Yatham et al., 2009). Whatsoever, implementing effective
treatments for maintenance therapy of BD continues to rep-
resent a significant clinical challenge.
Number needed to treat (NNT), a measure of effect size,
is a recommended tool for reporting results of clinical trials
for BD (Gray, 2004; Martinez-Aran et al., 2008). NNT summa-
rizes the effect of treatment in terms of the number of pa-
tients a clinician needs to treat with a particular therapy
to get a real responder to the drug. Calculation of NNT can
quantify the clinical relevance of a statistically significant
study result (Citrome 2008).
The aim of the present study was to compare the efficacy
profile of the drugs used for maintenance treatment of BD as
regards to their potential to prevent depressive versusmanic
episodes. For this purpose we have introduced a metric
named Polarity Index, a numeric expression of the efficacy
profile of a given drug obtained from NNT for prevention of
depressive episodes and NNT for mania prevention ratio.2. Experimental procedures
Randomized controlled trials (RCTs) of medications used for the
maintenance treatment of BD were systematically reviewed. A
comprehensive Pubmed search of all English-language articles pub-
lished up to June 2011 was performed. Terms ‘bipolar disorder’,
‘mania’, ‘mixed’, or ‘bipolar depression’, were cross-referenced
with trial characteristics search phrases and generic names ofmedications (approved or non-approved by regulatory agencies
for their use in BD).The search was supplemented by manually
reviewing reference lists from the identified publications.
Eligibility criteria were represented by randomized and double
blind trials and use of an mood stabilizer or antipsychotic drug
alone or in combination with a mood stabilizing agent such as lith-
ium or valproate, to treat adult patients with documented BD I or
II, with a placebo comparator. Included RCTs assessed the effec-
tiveness of drugs in the maintenance treatment of BD compared
to placebo with a minimal duration of 24 weeks, in patients aged
over 18. Exclusion criteria were a small sample size (meaning me-
dian sample inferior to 16.5 subjects in each group as suggested by
Richy et al., 2004, a study sample not exclusively composed of
bipolar patients and an absence of a placebo control group.
NNT was calculated by taking the reciprocals of the differ-
ences between the rates of the outcomes for two interventions.
Polarity Index was retrieved by dividing NNT for prevention of
depressive episodes and NNT for prevention of manic episodes.
When more studies regarding a single agent were available data
were combined using weighted mean.
A Polarity Index of 1.0 indicates equal efficacy of a drug in
prevention of manic and depressive episodes. Drugs with a
Polarity Index superior to 1.0 may have stronger antimanic
versus antidepressant prophylactic properties, while those
with Polarity Index inferior to 1.0 are more effective for pre-
venting depressive episodes than the manic ones.3. Results
Sixteen studies satisfied the inclusion criteria. The characteris-
tics of the RCTs that were finally included, alongside the results
as published in the original studies, are reported in Table 1. All
studies had an acute treatment phase, followed by a double-
blind, relapse-prevention (maintenance) treatment phase.
Some of the RCTs used a three-arm design and thus could be
used to make two comparisons each.
Table 2 provides NNTs for recurrence prevention of manic
and depressive episodes and Polarity Index for agents recom-
mended for long-term treatment of BD.
Predominantly Antimanic Polarity Index was found for risperi-
done LAI (PI=12.09) (Macfadden et al., 2009; Quiroz et al., 2010;
Vieta et al., accepted for publication) aripiprazole (PI=4.38) (Keck
et al., 2007; Marcus et al., 2011) and ziprasidone (Bowden et al.,
2010) (PI=3.91), followed by olanzapine (Tohen et al., 2006; Tohen
et al., 2004; Vieta et al., accepted for publication) (PI=2.98) and
lithium (PI=1.39) (Bowden et al., 2000; Bowden et al., 2003;
Calabrese et al., 2003; Prien et al., 1973; Weisler et al., 2008).
Quetiapine has the closest to 1.0 Polarity Index among the
agents assessed (PI=1.14) (Suppes et al., 2009; Vieta et al.
2008a; Weisler et al., 2008), while lamotrigine (PI=0.40) (Bowden
et al., 2003; Calabrese et al., 2003), oxcarbazepine (PI=0.62)
(Vieta et al., 2008b) and valproate (Bowden et al., 2000)
(PI=0.49) have Predominantly Antidepressive Polarity Index.
Logarithmic distribution of Polarity Index for the assessed
medicaments is depicted in Fig. 1.4. Discussion
This study provides a new metric to measure the relative
prophylactic efficacy of drugs used in bipolar disorder
Table 2 Number needed to treat for prevention of manic and depressive episodes and Polarity Index for medicaments used in
long-term treatment of bipolar disorder.
NNT NNT Polarity
Mania Depression Index
Aripiprazole-weighted mean Keck et al., 2007; Marcus et al., 2011 8.81 38.55 4.38
Aripiprazole monotherapy Keck et al., 2007 6.2 50 8.06
Aripiprazole combined with lithium/divalproex Marcus et al., 2011 10 33.3 3.33
Lamotrigine Bowden et al., 2003; Calabrese et al., 2003 50.4 20.2 0.40
Lithium Bowden et al., 2003; Calabrese et al., 2003; Weisler et al., 2008;
Prien et al., 1973; Bowden et al., 2000
4.4 6.1 1.39
Olanzapine-weighted mean Tohen et al., 2004, Tohen et al., 2006;
Vieta et al., accepted for publication
4.7 14 2.98
Olanzapine monotherapy Tohen et al., 2006; Vieta et al., accepted for publication 4.4 17.2 3.90
Olanzapine combined with lithium/divalproex Tohen et al., 2004 11.2 6.2 0.55
Oxcarbazepine Vieta et al., 2008b 8.2 5.1 0.62
Quetiapine-weighted mean Weisler et al., 2008; Vieta et al., 2008a; Suppes et al., 2009 3.5 4 1.14
Quetiapine combined with lithium/divalproex Vieta et al., 2008a; Suppes et al., 2009 7.1 5.9 0.83
Quetiapine monotherapy Weisler et al., 2008 2.4 3.3 1.38
Risperidone LAI Vieta et al., accepted for publication; Quiroz et al., 2010;
Macfadden et al., 2009
4.4 53.2 12.09
Risperidone LAI monotherapy Vieta et al., accepted for publication; Quiroz et al., 2010 4 36.4 9.1
RLAI+treatment as usual Macfadden et al., 2009 7.9 15.8 2
Valproate Bowden et al., 2000 21.3 10.5 0.49
Ziprasidone Bowden et al., 2010 14.1 55.1 3.91
343Polarity index of drugs for Bipolar Disordermaintenance. It is also the first study aiming to determine
the effectiveness profiles of the first-choice pharmacologi-
cal treatment options for maintenance treatment of BD
according to predominant polarity. As some patients are
more prone to relapse into mania and others more prone to
relapse into depression, the characterization of the polarity
index of drugs used in maintenance treatment of BD appears
clinically useful.
An emerging body of evidence indicates that predomi-
nance of episode polarity over the course of BD has beenLAM= lamotrigine, VPA= valproate, OXC= oxcarbazep
olanzapine, ZIP= ziprasidone, ARI= aripiprazole, RLAI=
Figure 1 Logarithmic distribution of Polarity Index for the aassociated with treatment response and outcome of subse-
quent acute episodes (Vieta et al., 2009) and thus should
be considered when determining the most appropriate ther-
apeutical strategy for prophylaxis of BD.
According to the results, aripiprazole, risperidone LAI,
ziprasidone and olanzapine have a high Polarity Index, indi-
cating better mania-prevention than depression prevention
properties. Likewise, lithium shows somewhat stronger anti-
manic than antidepressive properties, with a Polarity
Index slightly superior to 1.0. Quetiapine has Polarity Indexine, QUE= quetiapine, LI= lithium, OLZ= 
 risperidone long-acting injectable
gents used in maintenance treatment of Bipolar Disorder.
344 D. Popovic et al.closest to 1.0, indicating its balanced, slightly stronger
mania-recurrence preventing action. Among the drugs with
Polarity Index inferior to 1.0, suggesting higher effective-
ness in prevention of depressive episodes over manic and hy-
pomanic ones, lamotrigine seems a valid therapeutic option
for BD patients with predominant depressive recurrences.
The Polarity Index for valproate and for oxcarbazepine ap-
pears to be lower than 1.0 but it should be interpreted
with caution because the pivotal trials did not show statisti-
cal superiority of those two drugs over placebo. Data from
negative or failed studies has been considered in this metric
for drugs that have at least one positive maintenance trial,
but for those drugs with no positive studies it makes little
sense to speculate on their Polarity Index.
The present paper highlights the paucity of randomized
placebo-controlled studies for maintenance treatment of
BD. Given the scarcity of RCTs and in the interest of present-
ing most complete available data we have included both pla-
cebo-controlled trials assessing drugs in monotherapy and as
combination therapies. Since the combination therapy trials
were designed to assess the efficacy of drugs vs. placebo just
like monotherapy trials and the baseline therapy is stratified
and thus should not influence Polarity Index, mean Polarity
Index for each drug was calculated from pooled data from
all the published trials; Whatsoever, we have also reported
Polarity Index values calculated separately for monotherapy
vs. polytherapy studies, when available (see Table 2).
Randomized clinical trials for maintenance treatment of
Bipolar Disorder are not only scarce; they are completely
lacking for various agents. Carbamazepine is a clear exam-
ple; although it was the first agent after lithium to be advo-
cated for long-term treatment of BD and 2 lithium-
controlled studies indicate drug's efficacy in relapse preven-
tion (Greil et al., 1997; Hartong et al., 2003), by the time
the research was conducted there were no available long-
term placebo-controlled trials and thus Polarity Index of car-
bamazepine, could not be calculated. Future research needs
to address the long-term effectiveness and the polarity
index of agents such as carbamazepine, oxcarbazepine,
valproate and newer antipsychotics such as paliperidone or
asenapine.
The Polarity Index is a clinically useful measure, but has
some limitations; it has been derived from clinical trial
data and, therefore, issues related to trial design itself
might have influenced the results. These issues include the
abovementioned adjunctive versus monotherapy design as
well as the index episode. Recent literature suggests that
the polarity of the index episode tends to predict the polar-
ity of relapse into a subsequent episode in a ratio of about
2:1 to 3:1 and influences response to treatment (Calabrese
et al., 2004). A limitation of the present study is that most
maintenance trials, from which Polarity Index was calculat-
ed, with few exceptions, enrolled enriched populations of
patients who were currently or recently manic or mixed
(see Table 1). Missing from most study designs was the re-
cruitment of patients with index depressive episodes. Exclu-
sion of depressed patients at enrollment may affect the
polarity of mood episodes during the blinded relapse preven-
tion phase since the study design was primarily configured to
demonstrate efficacy in the delay or prevention of manic re-
currence. The absence of depressive index episodes in a
compound whose primary spectrum of efficacy is indepression, biases outcome against the drug, or vice versa;
which reflects in Polarity Index calculation as well. Howev-
er, the main reason why some compounds have only been
studied in the context of index mania is their failure to sep-
arate from placebo in acute bipolar depression trials; hence,
the bias against index depression is actually caused by the
high polarity index of the drug, which makes it more suitable
for the treatment of mania and the prevention of subsequent
manic episodes, and for this reason we believe that the po-
larity index is still fully valid and informative. Hence, Polar-
ity Index should be seen as a concept in continuous
evolution, apace with the ongoing research. Although we
have included all the available studies published up to
date, future studies might influence Polarity Index values,
especially for agents assessed in a small number of RCTs.
On a different matter, the Polarity Index does not say
anything about the absolute efficacy of the drug, but about
the efficacy profile (the higher the number, the more biased
toward preventing mania as opposed to preventing depres-
sion). Polarity Index is a ratio, which does not provide infor-
mation on NNT of each drug, but rather tells us how
balanced a drug's action is. Clinicians should consider both
of these concepts, NNT for preventing any mood episode
(Popovic et al., 2011) and the Polarity Index, separately,
when implementing a therapy; the NNT is a measure of the
profile of a drug, which, along with drug tolerability, may
help treatment choice in the context of personalized
medicine.
This is not necessarily a limitation, but an issue to take
into account. This metric may help, in the absence of a suf-
ficient number of comparative long-term trials, to under-
stand the relative efficacy profile of the drugs used in
maintenance treatment of BD.
Overall, our findings indicate that anticonvulsants, and
particularly lamotrigine, appear more effective for preven-
tion of depressive episodes, while atypical antipsychotics
and lithium may have a preponderant mania recurrence-
preventing action. Interestingly, although not surprisingly,
among the Second Generation Antipsychotics, Polarity
Index seems to correlate with the affinity for dopamine
type 2 (D2) receptors. Namely, aripiprazole (Ki=0.4 nm), ris-
peridone (Ki=2.2 nm) and ziprasidone (Ki=3.1 nm), drugs
with most potent affinity for D2 receptors (Schatzberg and
Nemeroff, 2009), have the highest Polarity Index, followed
by olanzapine (Ki=20 nm) and, finally, quetiapine
(Ki=180 nm). In fact, with the exception of aripiprazole,
the affinity for D2 receptors directly correlates with Polarity
Index. However, this may be due to the fact that aripipra-
zole is a partial agonist of D2 receptors, which in fact
means that, despite a high D2 affinity, the dopamine block-
ade capacity may be inferior to that of drugs with slightly
lower affinity for the D2 receptor, such as risperidone. The
implications of this finding are that the Polarity Index may
be influenced by the capacity of a given drug to reduce do-
pamine outflow in the brain, in the sense that the stronger
the antidopaminergic action, the higher the Polarity Index
and the greater the bias toward preventing mania rather
than depression.
According to the British Association for Psychopharmacol-
ogy guidelines (Goodwin 2009) different drugs should be pre-
scribed according to the predominance of manic or
depressive episodes. Since a patient with a predominant
345Polarity index of drugs for Bipolar Disorderdepressive polarity is much more likely to relapse into a de-
pressive episode, and therefore a suitable prophylaxis for
that patient might be an agent that has been shown to
have significant efficacy in preventing relapse of depressive
episodes, such as lamotrigine. Similarly, a patient who has
predominant manic polarity might require a stronger anti-
manic prophylactic agent, such as an atypical antipsychotic
or lithium, in order to prevent further relapse of manic epi-
sodes. When combining drugs, it may be advisable to com-
bine those which have different Polarity Index in order to
have “complementary” efficacy profile, especially in pa-
tients who do not present a predominant polarity. On the
whole, Polarity Index may be a useful aid for clinicians in
the complex process of implementing maintenance therapy
for bipolar disorder.
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3. POLARITY INDEX OF PSYCHOLOGICAL 
INTERVENTIONS IN MAINTENANCE TREATMENT OF 
BIPOLAR DISORDER (Objective 2)  
3.1. Introduction 
The current first-line treatment for the long term management of 
bipolar disorder is represented by pharmacological treatment 
(Yatham et al., 2009; Vieta et al, 2011). Whatsoever, far-from-
satisfactory outcome even among medicated patients, with 
relapse rates ranging from 40-60% ( Tohen et al., 2006; Tohen et 
al., 2003, Judd et al.,2008), has lead to develop several 
psychological interventions, aiming to delay recurrences, prevent 
relapses  and reduce episode length, when combined with 
pharmacotherapy (Miklowitz, 2008, Schöttle et al.,2011).   
The targets of different psychological interventions may vary, 
although the boundaries are blurry, and often address similar 
ingredients. Important differences exist as to the content and 
structure of various psychological interventions and up to date no 
attempt was made to classify interventions according to their 
ability to prevent manic vs. depressive episodes. The utility of 
such a classification is obvious when considering that around 
50% of patients present with a marked predominant polarity 
 
 
defined as at least twice as many episodes of one pole of the 
disorder over the other (Colom et al, 2006), which is one of the 
strongest predictors of relapse into a specific episode polarity 
(Baldessarini et al, 2012). 
In bipolar disorder, benefits of an intervention, such as efficacy 
of a treatment in maintenance therapy, as emerging from the 
results of clinical trials, can be expressed in terms of Number 
Needed to Treat (NNT) (Martinez-Aran et al. 2008; Ketter et al., 
2011; Popovic et al., 2011). NNT is a measure of effect size, and 
calculation of the NNT reflects the number of patients a clinician 
needs to treat with a particular therapy to expect to prevent one 
adverse event (Citrome, 2008).  
Recently our group has developed the construct of “Polarity 
Index”, a novel metric depicting the relative antimanic versus 
antidepressive preventive efficacy of an intervention in Bipolar 
Disorder maintenance treatment (Popovic et al., 2012). Polarity 
Index derives from NNT to prevent depressive episodes and NNT 
for prevention of mania ratio (Polarity Index = NNT  depression 
prophylaxis / NNT mania prophylaxis). The aim of the present 
study is to calculate Polarity Index and rank the available 
 
 
psychological interventions according to their efficacy profile by 
the means of Polarity Index.  
 
3.2. Methods 
A comprehensive literature search of all the articles published up 
to May 2012 incorporating results of searches of Medline and 
Pubmed was performed.  
Search terms such as “bipolar disorder”, “mania”, “mixed 
episode”, or ‘bipolar depression’, were cross-referenced with  
“psychotherapy”, “psychological interventions”, “psychosocial 
interventions” and  trial characteristics search phrases. The search 
was supplemented by manually reviewing reference lists from the 
identified publications.     
We planned a priori the inclusion of studies meeting the 
following criteria: randomized controlled trials (RCTs) 
comparing efficacy of a psychological intervention versus a 
comparator group in bipolar disorder maintenance treatment in 
patients aged over 18. Exclusion criteria were a small sample size 
(median sample inferior to 16.5 subjects, as suggested by Richy 
et al., 2004), a study sample not exclusively composed of bipolar 
patients and the absence of a control group. 
 
 
Thirty-four trials were identified, and ten met the inclusion 
criteria. 
Names of authors, institutions or journals were not kept blind. 
NNT, a measure of effect size that expresses the number of 
patients a clinician needs to treat with a particular therapy to 
expect to prevent one adverse event, was calculated by taking the 
reciprocals of the differences between the rates of the outcomes 
for two interventions (Citrome, 2008). NNT for prevention of 
relapse into any episode, mania and depression for each treatment 
assessed was calculated from the reports of all the studies that 
fulfilled the inclusion criteria. 
Polarity Index is a metric indicating the relative antimanic versus 
antidepressive preventive efficacy of interventions. PI was 
retrieved by calculating NNT for prevention of depression and 
NNT for prevention of mania ratio, as emerging from the results 
of randomized placebo-controlled trials. PI value above 1.0 
indicates relatively higher antimanic prophylactic properties, 
while a number below 1.0 indicates a relatively greater 
antidepressive action (Popovic et al., 2012). 
 
 
 
 
3.3. Results 
Ten studies satisfied the inclusion criteria, but it was possible to 
calculate Polarity Index for 9 of them. The characteristics of the 
RCTs that were finally included, alongside the results as 
published in the original studies, are reported in Table 1.  
Excluded trials, alongside with the reason of their exclusion, are 
shown in Table 2. Table 3 provides NNTs for recurrence 
prevention of manic, depressive and any mood episode alongside 
with Polarity Index for adjunctive psychotherapies in long-term 
treatment of bipolar disorder for all the RCTs where it was 
possible to calculate NNT, and thus Polarity Index. 
Predominantly antidepressive Polarity Index was found for 
cognitive behavioural therapy, with values of 0.33 and 0.63 at 12 
months and 30 months, respectively, in studies by Lam et al. 
(Lam et al., 2003; Lam et al., 2005); Polarity Index of  0.42 was 
found for family-focused therapy (Miklowitz et al., 2003). A 
predominantly antidepressive Polarity Index of 0.73 was found 
for psychoeducation after a 2-year follow-up ( Colom et al., 
2003), and 0.78 at 5-year follow-up (Colom et al., 2009).  
Predominantly antimanic Polarity Index of 1.78 was found for 
caregiver group psychoeducation (Reinares et al., 2008).  
 
 
Polarity Index of 1 found for enhanced relapse prevention 
(Lobban et al., 2010), 3.36 found for brief technique-driven 
interventions (Perry et al.,1999), and 0.89 for cognitive 
behavioural therapy in the study by Meyer and Hautzinger (2011)  
can not be considered as reliable since the trials were negative.  
Logarithmic distribution of Polarity Index for the assessed 
interventions is depicted in the following figure:  
 
 
PI= Polarity Index, CBT= cognitive behavioural therapy, FFT= family-focused therapy, PE= 
psychoeducation 1Lam et al., 2003; 2Lam et al., 2005; 3Miklowitz 2003;  , 2011; 4Colom et 
al.,2003; 5Colom et al., 2009;; 7Reinares 2008  
 
 
 
 
 
 
 
 
3.4. Discussion and Conclusions 
This study applies Polarity Index, a novel metric developed to 
measure the relative prophylactic efficacy profile of medicaments 
in bipolar disorder, to all available psychological interventions. 
To the best of our knowledge, this is the first paper aiming to 
determine the efficacy profiles in relapse prevention of 
depressive vs. manic episodes of psychological treatments used 
as adjuvants to pharmacotherapy in maintenance treatment of 
bipolar disorder.  
As some patients are more prone to relapse into mania and others 
more prone to relapse into depression, the characterization of the 
polarity index of psychotherapeutic interventions used in 
maintenance treatment of BD appears clinically useful. 
According to the results that emerged, cognitive behavioural 
therapy, family-focused therapy and psychoeducation had 
Polarity Index below 1.0, indicating their more antidepressive 
than antimanic prophylactic effects, while caregiver group 
psychoeducation had Polarity Index above 1.0, indicating a 
prevalently antimanic action. Three studies, one cognitive 
behavioural therapy trial (Meyer and Hautzinger, 2011), 
enhanced relapse prevention (Lobban et al., 2010) and brief 
 
 
technique-driven interventions (Perry et al.,1999), have Polarity 
Index of 0.89, 1 and 3.36, respectively, but can not be considered 
reliable since the NNT for prevention of any mood episode was 
not statistically significant, and the trials themselves were 
negative. Furthermore, Polarity Index could not be calculated for 
cognitive behavioural therapy by Scott et al. (2006), since not 
only was the NNT for prevention of any episode not significant, 
but NNT for prevention of depressive episodes could not be 
calculated because there was the same number of depressive 
relapses in the intervention group as in the control group. 
Numerous studies did not report relapse rates into mania and 
depression separately and thus we were unable to calculate their 
Polarity Index (See Table 2). 
Interestingly, in both of the only two of the abovementioned trials 
that presented extended follow-up results (Lam et al.,2003, Lam 
et al.,2005, Colom et al.,2003, Colom et al.,2009) both 
interventions showed a trend in shifting towards PI of 1 over 
time, namely towards a more balanced action. 
The implications of these results are multiple; above all PI may 
guide the clinician into deciding which intervention may be more 
indicated for a single patient. Comparably to pharmacological 
 
 
interventions in bipolar disorder, or any kind of intervention in 
medicine for that matter, not all the interventions are equally 
suitable for each patient; thus Polarity Index may represent an 
useful tool to help the clinicians to select the most appropriate 
intervention for each patient in the era of personalized medicine.  
This may be useful in treatment election suggesting that, for 
example, patients with predominant depressive polarity may 
benefit more from cognitive behavioural therapy, family-focused 
therapy or psychoeducation, while caregivers of patients with 
predominant manic polarity may be advised to undertake 
psychoeducation for caregivers. Moreover, combining patient 
psychotherapy and caregiver-oriented interventions may help 
achieve a more balanced, complementary, Polarity Index.  
Future studies are needed in order to isolate the “active 
ingredients” responsible for therapeutic response and thus enable 
to design new, eventually shorter, interventions that would focus 
on the essential components in order to prevent episodes of 
different polarity.  This study also evidences paucity of trials 
assessing long-term efficacy of adjunctive psychotherapeutic 
interventions. Above all, it underlines the scarcity of 
interventions efficacious for predominantly manic patients. 
 
 
Interestingly, this is precisely the opposite situation as for drugs 
PI. Most available maintenance pharmacotherapies for bipolar 
disorder have PI above 1, meaning that they are better preventing 
mania than depression (Popovic et al, 2012). Psychological 
interventions appear better to prevent depression than mania, 
with the exception of those with more educational components or 
working through relatives, who may be particularly motivated or 
skilled to prevent mania, rather than depression. Interventions 
based on patient participation or with more cognitive and face-to-
face participation may be more effective preventing depression. 
The main limitation (and strength!) of the Polarity Index is the 
fact that it derives from RCT data, meaning that issues related to 
trial design may influence Polarity Index calculations. Among 
these, issues such as a lack of definition of “placebo comparator” 
for psychological interventions and uneven number or sessions 
(or even comparison of an adjunctive intervention to “Treatment 
As Usual” as control comparator), not only between different 
interventions, but also among the experimental and control 
intervention in the same study are evident. The medicaments that 
patients were assuming differ, and were often not specified.  
Study samples were extremely heterogeneous (as may be seen 
 
 
from “trial characteristics” column in Table 1); several trials 
included patients with Bipolar I or both Bipolar I and II 
diagnosis, euthymic or acute patients. Even the definition of 
“euthymia” (syndromic or symptomic) was not always uniform, 
as well as the required duration of euthymia. Differences in 
exclusion criteria, such as the number of previous episodes and 
presence of comorbid pathologies are also common between 
studies. Furthermore the used scales and outcome measures are 
highly heterogeneous. Above all, the name of intervention (e.g. 
cognitive behavioural therapy) does not necessarily mean that 
same treatment protocol was applied; reason why, unlike the 
Polarity Index for drugs, we were unable to pool data when more 
studies were available for one intervention.   
The Polarity Index does not say anything about the absolute 
efficacy of the intervention, but about the efficacy profile (the 
higher the number, the more biased toward preventing mania as 
opposed to preventing depression). It is a ratio, which does not 
provide information on NNT of each drug, but rather tells us how 
balanced an intervention is. Both of these concepts, NNT and the 
Polarity Index, need to be considered separately, NNT to 
 
 
determine the efficacy of an intervention, and Polarity Index to 
depict its profile.  
Polarity Index may guide treatment choice in the context of 
personalized patient care, not only for pharmacological 
treatments but also, and maybe even more so, given the lack of 
any similar tools, for adjunctive psychotherapeutic interventions. 
The fact that the PI of most pharmacotherapies and 
psychotherapies may be complementary should promote 
combinations of the two. This metric may help, in the absence of 
a sufficient number of comparative long-term trials, to 
understand the relative efficacy profile of adjunctive 
psychological interventions used in maintenance treatment of BD 
and perhaps design interventions with specific profiles. 
 
 
 
 
 
 
 
 
 
 
 
4. CLINICAL IMPLICATIONS OF PREDOMINANT 
POLARITY AND THE POLARITY INDEX OF DRUGS USED 
IN MAINTENANCE TREATMENT OF BIPOLAR 
DISORDER: A NATURALISTIC STUDY (Objective 3) 
 
4.1. Introduction 
The aim of the present study was to apply Polarity Index to real-
world setting. Secondary aim of this naturalistic study was to ally 
Polarity Index in order to assess eventual differences between 
predominantly manic and depressed patients, with a special focus 
on their pharmacological treatment.  
On these grounds we have calculated mean Polarity Index for 
current pharmacological treatment of 604 patients enrolled in 
Bipolar Disorders Program of the Hospital Clinic and University 
of Barcelona. The abovementioned program delivers evidence-
based treatment for patients with bipolar disorder in the context 
of a specialized setting (Vieta, 2011a; Vieta, 2011b; Rosa et al, 
2011). 
 The objective was to test whether clinicians were actually 
applying the concept of PI to their patients. Theoretically, 
patients with MPP would be receiving treatments with higher PI 
 
 
than patients with DPP. Since combination drug regimens are 
ubiquitous in clinical practice (Goldberg et al., 2009; Tamayo et 
al., 2010), Polarity Index was calculated as a mean of Polarity 
Index of all the prescribed drugs in each patient.  
 
4.2. Methods 
      Depressive predominant polarity (DPP) was defined as at 
least two-thirds of a patient's past episodes fulfilling DSM-IV 
criteria for Major Depressive Episode.   
Manic or hypomanic predominant polarity (MPP) was defined as 
at least two thirds of past episodes fulfilling DSM-IV criteria for 
manic or hypomanic episodes (Colom et al., 2006). Mixed 
episodes were counted for as well but were not considered as a 
part of Depressive Polarity or Manic Polarity. The patients that 
did not meet criteria for either predominant polarity were 
excluded from the analysis. 
   Polarity Index, a  metric indicating antimanic and 
antidepressive prophylactic potential of drugs, was retrieved by 
calculating NNT for prevention of depression and NNT for 
prevention of mania ratio (Popovic et al., 2012), as emerging 
from the results of  randomized placebo-controlled trials (Table 
 
 
4). NNTs were calculated as weighted mean from the results of 
all published studies that satisfied the following inclusion 
criteria: randomized and double blind studies, with a minimal 
duration of 24 weeks, assessing effectiveness of a mood stabilizer 
or an antipsychotic drug alone or in combination with a mood 
stabilizing agent versus a placebo comparator as maintenance 
treatment in patients affected by Bipolar Disorder type I or II and 
aged ≥ 18 (Popovic et al., 2011). 
 A Polarity Index of 1 indicates equal efficacy of a drug in 
prevention of manic and depressive episodes. Drugs with a 
Polarity Index superior to 1 may have stronger antimanic versus 
antidepressant prophylactic properties, while those with Polarity 
Index inferior to 1 are more effective for preventing depressive 
episodes than the manic ones. 
Polarity Index was calculated for current treatment of each 
patient. When patients received more than 1 pharmacological 
treatment Polarity Index was calculated as mean of all the 
prescribed treatments; e.g. Polarity Index of patient treated with 
Lithium and Lamotrigine is calculated as following:  
[1.52 (Polarity Index Lithium) + 0.74 (Polarity Index 
Lamotrigine)] / 2 (number of drugs) = 1.13] 
 
 
Polarity Index of 1.13 suggests a balanced, slightly more 
antimanic than antidepressive profile of the drug regimen. 
Study Sample 
The study sample is composed of 604 consecutive patients 
enrolled in the systematic prospective naturalistic follow-up 
study of the Bipolar Disorders Program of the Hospital Clinic 
and University of Barcelona, a tertiary center providing 
integrated care for patients from a specific catchment area as well 
as difficult-to-treat bipolar patients derived from all over Spain, 
ongoing from 1994 up to date, as already described elsewhere 
(Colom et al., 2006; Nivoli et al., 2011). The systematic 
prospective follow-up was approved by the Ethical and Research 
Committee of the Hospital University Clinic. 
 Patients’ clinical and sociodemographic data were systematically 
collected on bimonthly bases. Eligibility criteria were represented 
by age ≥18, fulfilling DSM-IV TR criteria for Bipolar I or II 
Disorder and providing written informed consent. 
Data collection 
Psychiatric diagnoses were formulated by senior psychiatrists 
according to DSM-IV-TR criteria and confirmed by Structured 
Clinical Interview for DSM-III-R-axis I (SCID-I) and axis II-
 
 
SCID-I and SCID-II (Spitzer et al., 1990). Episodes were 
prospectively assessed through DSM-IV check list for mania, 
hypomania, mixed episodes or depression. Clinical variables, 
such as number and polarity of previous episodes, number of 
hospitalizations, age at onset, age of first hospitalization, polarity 
of first episode, history of psychosis and suicidal behavior, were 
obtained from the structured interviews with patients and their 
relatives. Several more variables were specifically assessed; 
namely: demographic data, medical and psychiatric 
comorbidities, and psychiatric history of first-degree relatives, 
seasonality and  rapid cycling (according to DSM-IV criteria), 
while information regarding social and occupational functioning 
and presence of life-events related to illness onset were assessed 
by the means of the Holmes and Rahe inventory (Holmes and 
Rahe, 1967). 
Patients were divided into two groups on the basis of the type of 
Predominant Polarity: DPP and MPP. The two groups were 
compared regarding clinical and sociodemographic variables as 
well as regarding Polarity Index, which was calculated for 
current pharmacological treatment of each patient. 
 
 
 
Statistical Analyses 
Descriptive analyses were utilized for the definition of the 
frequencies. Continuous variables were compared by Student’s t-
tests and ANOVA and categorical variables by Pearson Chi-
square with Yates' correction and Fisher’s exact test for the 
comparison of categorical data ( value, two tailed). Mean 
differences in quantitative variables with a non-normal 
distribution were assessed by Mann-Whitney U test for 
independent variables. Given the exploratory nature of our study 
we did not apply corrections for multiple comparisons, and alpha 
level was set at the .05 level (2-tailed). Statistical analyses were 
performed using the Statistical Package for Social Sciences 
(SPSS, 18.0 version for Windows).  
4.3. Results 
Three hundred forty-seven patients (57.45 %) out of the first 
consecutive 604 patients screened were excluded from the 
analyses since they did not present a specific predominant 
polarity according to the definition by Colom et al. (2006).The 
mean duration of follow-up for our sample was 10.4 years 
(SD=4.97). Two hundred fifty-seven patients (n=257, 52.55 %) 
fulfilled the inclusion criteria. One hundred forty-three patients 
 
 
(n=143, 55.6 %) were classified as Depressive Polarity, whilst 
one hundred fourteen (n=114, 44.4 %) patients fulfilled criteria 
for Manic Polarity.  
 Demographic characteristics, global social functioning variables 
and clinical qualitative features are shown in Table 5.  
Regarding demographic and global social functioning variables, 
MPP and DPP groups presented with only one significant 
difference (gender); hence, male patients were more likely to 
have MPP.  As to the distinguishing clinical features, the MPP 
group presented significantly with higher prevalence of Bipolar 
Disorder I diagnosis, substance use prior to the illness onset and 
more psychotic symptoms (lifetime and at onset) than the DPP 
group. In contrast, Depressive Polarity group was strongly 
associated with Bipolar II diagnosis, depressive onset, presence 
of life events preceding first episode, the presence of melancholia 
and suicide attempts rate. 
Differential quantitative features between MPP and DPP groups 
are shown in Table 6. MPP patients presented with younger age, 
younger age at onset and younger age at first hospitalization, 
more hospitalizations as well as more manic and hypomanic 
episodes. Depressive episodes were more frequent in the DPP 
 
 
group, whilst no difference was detected between the two groups 
regarding total number of episodes, number of mixed episodes 
nor number of suicide attempts.  
Table 7 provides the Polarity Index reflecting current 
pharmacological treatment of the two groups. Total Polarity 
Index (calculated as mean value of Polarity Index of all 
prescribed antipsychotics and mood stabilizers in each patient), 
as well as Polarity Index of antipsychotics and mood stabilizers 
taken separately, were higher, indicating a stronger antimanic 
regimen, in the MPP group.  
Table 8 summarizes the current pharmacological treatment of 
Manic Polarity and Depressive Polarity patients. When analyzing 
single drugs, the prescription of First Generation Antipsychotics 
and Second Generation Antipsychotics Olanzapine and 
Risperidone was significantly more frequent among MPP 
patients, whilst use of Lamotrigine, Selective Serotonin Reuptake 
Inhibitors (SSRIs), Serotonin–Norepinephrine Reuptake 
Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs) and 
Benzodiazepines was more prevalent amongst DPP patients. 
Interestingly, lithium showed a trend for higher prescription rate 
 
 
in the Manic Polarity group, but without reaching statistical 
significance (χ²=3.521, p=0.061).  
4.4. Discussion 
The present study aimed to apply Polarity Index, a novelmetric 
aiming to help clinicians to understand the prophylactic efficacy 
profile of drugs used for treatment of Bipolar Disorder, to real-
world clinical practice.  
  The results of the present study confirm that, in clinical settings, 
the maintenance treatment of Bipolar Disorder is in accordance 
with the results emerging from data retrieved from randomized 
clinical trials by calculating NNT for prevention of depression vs. 
mania ratio; namely, patients with MPP presented significantly 
higher Polarity Index, indicating that clinicians chose a treatment 
regimen with stronger antimanic prophylactic action, than for 
DPP patients. The same was true for Polarity Index of Atypical 
Antipsychotics and Polarity Index of Mood Stabilizers when 
analysed separately. When examining the prevalence of 
prescription of single mood stabilizing drugs, lamotrigine was 
prescribed more frequently in patients with DPP, alongside with 
most antidepressants (TCAs, SSRI and SNRIs) and 
 
 
benzodiazepines. In comparison, Risperidone, Olanzapine and 
Neuroleptics were prescribed more often in the MPP group. 
In addition to different pharmacological treatment, several 
clinical differences were detected between the groups. The 
present study confirms most of the findings reported by Colom et 
al. (2006). Main differences, probably due to a larger study 
sample, involved gender, history of psychotic symptoms, 
substance use preceding first episode and seasonal pattern. Other 
findings were consistent, as expected with data from our group 
(Nivoli et al 2011; Undurraga et al, 2011) but also from 
independent samples from other areas, countries, and continents 
(Rosa et al, 2008; Mazzarini et al, 2009;González-Pinto et al, 
2010; Baldessarini et al, 2012). 
In summary, MPP was associated with male gender, younger age, 
younger age at illness onset, younger age of first hospitalization, 
higher hospitalization rate, more manic and hypomanic episodes. 
Regarding clinical features, MPP was associated with Bipolar 
Disorder I primary substance abuse and psychotic symptoms. 
Factors associated with DPP were Bipolar Disorder II, depressive 
onset, more depressive episodes, stressful events preceding 
illness onset, more suicide attempts and melancholic features. 
 
 
These data are mostly in accordance with recently reported 
findings by Baldessarini et al., (2012), who detected that 
Predominant Depression was associated with depressive or mixed 
onset, more mixed-states, and higher suicidal risk and that 
Predominant Mania was associated with initial mania or 
psychosis and more family history. 
 
4.5. Limitations 
Limitations of the present study include the tertiary-centre nature 
of the Barcelona Bipolar Program at Hospital Clinic, which 
includes a high percentage of difficult-to-treat patients, as well as 
issues regarding Polarity Index metric. Id est, Polarity Index 
could not be calculated for all drugs used in treatment of Bipolar 
Disorder since long-term trials were not conduced for all the 
agents. In some cases, as for Valproate and Oxcarbazepine, 
Polarity Index may not be reliable due to the failure to separate 
from placebo during the pivotal maintenance treatment studies, 
thus we have excluded them from the analysis. Polarity Index 
was retrieved from results of clinical trials, thus issues related to 
trial design itself (adjunctive versus monotherapy design, 
enrollment of enriched populations of patients who were mainly 
 
 
currently or recently manic or mixed) may have biased the results 
as discussed in the primary paper on Polarity Index (Popovic et 
al., 2012).An interesting issue is that most maintenance trials 
assessed samples enriched for efficacy; however, lamotrigine 
trials were unique in sense that they included study sample 
enriched for tolerability, and not efficacy, which may have 
accounted for to the high NNT detected for lamotrigine (50.4 for 
mania prevention and 20.2 for prevention of depression) 
(Popovic et al., 2011; Bowden et al., 2003; Calabrese et al., 
2003). It is important to remember that Polarity Index is not a 
measure of the absolute efficacy of a drug, like NNT, but it rather 
describes the drug profile; in the case of lamotrigine, although the 
trial design may have influenced the efficacy reflected in NNT 
calculation, it is not reflected in Polarity Index which, with the 
value of 0.40, indicates that lamotrigine is more antidepressant 
than antimanic. 
 
4.6. Conclusions  
Predominant polarity, proposed as a course specifier of particular 
relevance for long-term therapeutic decision-making process and 
outcome predictor (Tohen et al., 2009) in DSM-V (Colom and 
 
 
Vieta, 2009), finds its clinical expression in Polarity Index. The 
present study not only provides further evidence to the 
importance of considering patients’ predominant polarity, but 
also examines the actual use of the Polarity Index in routine 
clinical practice. 
The results of the present naturalistic study confirm the 
usefulness of Polarity Index metric in maintenance treatment of 
BD. Important clinical differences between predominantly manic 
and predominantly depressed patients emerged, and justify the 
need for differentiated therapeutic approach in the two groups. 
Our study shows that the treatment of patients with MPP was 
oriented mostly towards mania prevention, as evidenced by 
higher Polarity Index, while treatment of DPP patients was 
characterized by lower mean Polarity Index, thus directed 
towards preventing depression. Likewise, the choice of the 
specific drug, even within the same class, varied in accordance 
with patients’ predominant polarity- Second Generation 
Antipsychotics with stronger antimanic vs. antidepressant 
properties were prescribed more often in the Manic Polarity 
group, and vice versa, mood stabilizers with lower Polarity Index 
were prescribed more frequently in Depressive Polarity patients. 
 
 
Assuming that specialized care centres may provide higher 
standards of care and better outcomes than non-specialized 
settings (Kessing et al, in press), the Polarity index may be 
helpful as a tool to assess the quality of maintenance prescription 
for bipolar patients; hence, if MPP patients receive higher PI 
regimens than DPP patients, the treatment is likely to be evidence 
based. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. GENERAL DISCUSSION 
Due to the episodic and chronic nature of the illness, maintenance 
therapy is a critical part of treatment for bipolar disorder. The 
ultimate goal of treatment is the prevention of episode recurrence 
through the long-term management of the symptoms (Thase, 
2008).  
Scientific evidence concerning the treatment of affective 
disorders is even more complex given the low reliability and 
validity of diagnosis, as well as for the fact that a specific and 
different treatment needs to be considered separately for manic, 
hypomanic, mixed, and depressive episodes. Even drugs proven 
effective for the acute phase of either pole in each patient are 
often not adequate in the maintenance phase (Fountoulakis et al., 
2012). 
The main aims of this dissertation are to introduce a clinician-
friendly metric that would enable to compare the efficacy profiles 
of the drugs and of adjunctive psychological interventions used 
for maintenance treatment of bipolar disorder as regards to their 
potential to prevent depressive versus manic episodes. 
Subsequently, Polarity Index metric was to be applied to real-
world setting, in a naturalistic study, to a large sample of bipolar 
 
 
patients, in order to assess the external validity of the metric.  
The secondary aim was to ally Polarity Index in order assess 
eventual differences between predominantly manic and 
predominantly depressed patients, with a special focus on their 
pharmacological treatment.  
NNT is a useful and meaningful concept for practicing clinicians 
which may help to translate the results of randomized controlled 
clinical trials to evidence-based medicine (Martinez-Aran et al., 
2008). Nonetheless, most of the published studies have not 
reported NNT values for assessed medicaments.   
NNT analysis evidenced differences in efficacy profiles among 
various agents used as first-line maintenance treatment for 
bipolar disorder. In general, our findings are in agreement with 
the recommendations of recent guidelines for the maintenance 
therapy of bipolar disorder (Yatham et al. 2009). Aripiprazole, 
olanzapine, quetiapine, risperidone LAI, ziprasidone, lithium, 
lamotrigine, and valproate have single-digit NNTs and are 
significantly effective for the prevention of any mood episode, 
but show substantial differences as to their ability to prevent 
mania and depression separately. Among the agents assessed, the 
only exception is given by oxcarbazepine combined with lithium 
 
 
that had a significant single-digit NNT for prevention of any 
episode, mania, and depression, but CI did not result significant, 
probably for the lack of power due to the relatively small sample 
size. 
The NNT analyses confirmed the efficacy of quetiapine (in 
monotherapy and combined with mood stabilizer), lithium, 
risperidone LAI, aripiprazole, and olanzapine in preventing 
manic recurrences. Lamotrigine, lithium, and quetiapine alone 
and combined with lithium/valproate presented significant NNTs 
for the prevention of depressive relapses. The data emerging 
from our analysis provide utter evidence that the treatments 
assessed differentiated in terms of whether they primarily prevent 
mania or depression or have bidirectional effects. The clinical 
relevance of the directional efficacy of the various medications is 
heightened in the context of predominant polarity, a parameter 
correlated with treatment response and outcome of later acute 
episodes (Vieta et al. 2009; Colom et al. 2006); nevertheless, 
placebo-controlled randomized clinical trials assessing long-term 
effectiveness of mood stabilizers and antipsychotics are 
surprisingly sparse, and important questions remain unanswered. 
An apparent paradox emerges from NNT values analyses. 
 
 
Namely, it may seem surprising that NNT for the prevention of 
any mood episode is often smaller than NNT for the prevention 
of manic or depressive relapses separately; however, one should 
bear in mind that the included studies were designed to assess 
efficacy in terms of prevention of any mood episode as primary 
aim. 
The following step was to introduce a metric indicative of 
relative prophylactic efficacy of drugs used in bipolar disorder 
maintenance. It is also the first study aiming to determine the 
effectiveness profiles of the first-choice pharmacological 
treatment options for maintenance treatment of bipolar disorder 
according to predominant polarity (Popovic et al., 2012). As 
some patients are more prone to relapse into mania and others 
more prone to relapse into depression, the characterization of the 
Polarity Index of drugs used in maintenance treatment of bipolar 
disorder appears clinically useful. 
An emerging body of evidence indicates that predominance of 
episode polarity over the course of bipolar disorder has been 
associated with treatment response and outcome of subsequent 
acute episodes (Vieta et al., 2009) and thus should be considered 
when determining the most appropriate therapeutical strategy for 
 
 
prophylaxis of bipolar disorder. 
According to the results, aripiprazole, risperidone LAI, 
ziprasidone and olanzapine have a high Polarity Index, indicats 
better mania prevention than prevention of depressive episodes. 
Likewise, lithium shows somewhat stronger antimanic than 
antidepressive properties, with a Polarity Index slightly superior 
to 1.0. Quetiapine has Polarity Index closest to 1.0, indicating its 
balanced, slightly stronger mania-recurrence preventing action. 
Among the drugs with Polarity Index inferior to 1.0, suggesting 
higher effectiveness in prevention of depressive episodes over 
manic and hypomanic ones, lamotrigine seems a valid therapeutic 
option for bipolar disorder patients with predominant depressive 
recurrences. The Polarity Index for valproate and for 
oxcarbazepine appears to be lower than 1.0 but it should be 
interpreted with caution because the pivotal trials did not show 
statistical superiority of those two drugs over placebo. Data from 
negative or failed studies has been considered in this metric for 
drugs that have at least one positive maintenance trial, but for 
those drugs with no positive studies it makes little sense to 
speculate on their Polarity Index. 
The present dissertation highlights the paucity of randomized 
 
 
placebo-controlled studies for maintenance treatment of bipolar 
disorder. Given the scarcity of RCTs and in the interest of 
presenting most complete available data we have included both 
placebo-controlled trials assessing drugs in monotherapy and as 
combination therapies. Since the combination therapy trials were 
designed to assess the efficacy of drugs vs. placebo just like 
monotherapy trials and the baseline therapy is stratified and thus 
should not influence Polarity Index, mean Polarity Index for each 
drug was calculated from pooled data from all the published 
trials; Whatsoever, we have also reported Polarity Index values 
calculated separately for monotherapy vs. polytherapy studies, 
when available (Table 9). 
On a different matter, the Polarity Index does not say anything 
about the absolute efficacy of the drug, but about the efficacy 
profile (the higher the number, the more biased toward 
preventing mania as opposed to preventing depression). 
Polarity Index is a ratio, which does not provide information on 
NNT of each drug, but rather tells us how balanced a drug's 
action is. Clinicians should consider both of these concepts, NNT 
for preventing any mood episode (Popovic et al., 2011) and the 
Polarity Index, separately, when implementing a therapy; the 
 
 
NNT is a measure of the profile of a drug, which, along with drug 
tolerability, may help treatment choice in the context of 
personalized medicine. This is not necessarily a limitation, but an 
issue to take into account. This metric may help, in the absence 
of a sufficient number of comparative long-term trials, to 
understand the relative efficacy profile of the drugs used in 
maintenance treatment of bipolar disorder. 
Overall, our findings indicate that anticonvulsants, and 
particularly lamotrigine, appear more effective for prevention of 
depressive episodes, while atypical antipsychotics and lithium 
may have a preponderant mania recurrence preventing action. 
Interestingly, although not surprisingly, among the Second 
Generation Antipsychotics, Polarity Index seems to correlate 
with the affinity for dopamine type 2 (D2) receptors. Namely, 
aripiprazole (Ki=0.4 nm), risperidone (Ki=2.2 nm) and 
ziprasidone (Ki=3.1 nm), drugs with most potent affinity for D2 
receptors (Schatzberg and Nemeroff, 2009), have the highest 
Polarity Index, followed by olanzapine (Ki=20 nm) and, finally, 
quetiapine (Ki=180 nm). In fact, with the exception of 
aripiprazole, the affinity for D2 receptors directly correlates with 
Polarity Index. However, this may be due to the fact that 
 
 
aripiprazole is a partial agonist of D2 receptors, which in fact 
means that, despite a high D2 affinity, the dopamine blockade 
capacity may be inferior to that of drugs with slightly lower 
affinity for the D2 receptor, such as risperidone. The implications 
of this finding are that the Polarity Index may be influenced by 
the capacity of a given drug to reduce dopamine outflow in the 
brain, in the sense that the stronger the antidopaminergic action, 
the higher the Polarity Index and the greater the bias toward 
preventing mania rather than depression. 
According to the British Association for Psychopharmacology 
guidelines (Goodwin 2009) different drugs should be prescribed 
according to the predominance of manic or depressive episodes. 
Since a patient with a predominant depressive polarity is much 
more likely to relapse into a depressive episode, and therefore a 
suitable prophylaxis for that patient might be an agent that has 
been shown to have significant efficacy in preventing relapse of 
depressive episodes, such as lamotrigine. Similarly, a patient who 
has predominant manic polarity might require a stronger 
antimanic prophylactic agent, such as an atypical antipsychotic or 
lithium, in order to prevent further relapse of manic episodes. 
When combining drugs, it may be advisable to combine those 
 
 
which have different Polarity Index in order to have 
“complementary” efficacy profile, especially in patients who do 
not present a predominant polarity. On the whole, Polarity Index 
may be a useful aid for clinicians in the complex process of 
implementing maintenance therapy for bipolar disorder. 
Polarity Index was also calculated for all the available adjunctive 
psychological interventions to measure their relative prophylactic 
efficacy profile in patients with bipolar disorder. To the best of 
our knowledge, this is the first study aiming to determine the 
efficacy profiles in relapse prevention of depressive vs. manic 
episodes of psychological treatments used as adjuvants to 
pharmacotherapy in maintenance treatment of bipolar disorder.  
As some patients are more prone to relapse into mania and others 
more prone to relapse into depression, also the characterization of 
the Polarity Index of psychotherapeutic interventions used in 
maintenance treatment of bipolar disorder appears clinically 
useful. 
According to the results that emerged, cognitive behavioural 
therapy, family-focused therapy and psychoeducation had 
Polarity Index below 1.0, indicating their more antidepressive 
than antimanic prophylactic effects, while caregiver group 
 
 
psychoeducation had Polarity Index above 1.0, indicating a 
prevalently antimanic action. Three studies, one cognitive 
behavioural therapy trial (Meyer and Hautzinger, 2011), 
enhanced relapse prevention (Lobban et al., 2010) and brief 
technique-driven interventions (Perry et al.,1999), have Polarity 
Index of 0.89, 1 and 3.36, respectively, but can not be considered 
reliable since the NNT for prevention of any mood episode was 
not statistically significant, and the trials themselves were 
negative. Furthermore, Polarity Index could not be calculated for 
cognitive behavioural therapy by Scott et al. (2006), since not 
only was the NNT for prevention of any episode not significant, 
but NNT for prevention of depressive episodes could not be 
calculated because there was the same number of depressive 
relapses in the intervention group as in the control group. 
Numerous studies did not report relapse rates into mania and 
depression separately and thus we were unable to calculate their 
Polarity Index (See Table 2). 
Interestingly, in both of the only two of the abovementioned trials 
that presented extended follow-up results (Lam et al., 2003, Lam 
et al., 2005, Colom et al., 2003, Colom et al., 2009) both 
interventions showed a trend in shifting towards PI of 1 over 
 
 
time, namely towards a more balanced action. 
The implications of these results are multiple; above all PI may 
guide the clinician into deciding which intervention may be more 
indicated for a single patient. Comparably to pharmacological 
interventions in bipolar disorder, or any kind of intervention in 
medicine for that matter, not all the interventions are equally 
suitable for each patient; thus Polarity Index may represent an 
useful tool to help the clinicians to select the most appropriate 
intervention for each patient in the era of personalized medicine.  
This may be useful in treatment election suggesting that, for 
example, patients with predominant depressive polarity may 
benefit more from cognitive behavioural therapy, family-focused 
therapy or psychoeducation, while caregivers of patients with 
predominant manic polarity may be advised to undertake 
psychoeducation for caregivers. Moreover, combining patient 
psychotherapy and caregiver-oriented interventions may help 
achieve a more balanced, complementary, Polarity Index.  
Future studies are needed in order to isolate the “active 
ingredients” responsible for therapeutic response and thus enable 
to design new, eventually shorter, interventions that would focus 
on the essential components in order to prevent episodes of 
 
 
different polarity.  This study also evidences paucity of trials 
assessing long-term efficacy of adjunctive psychotherapeutic 
interventions. Above all, it underlines the scarcity of 
interventions efficacious for predominantly manic patients. 
Interestingly, this is precisely the opposite situation as for drugs 
Polarity Index. Most available maintenance pharmacotherapies 
for bipolar disorder have Polarity Index above 1, meaning that 
they are better preventing mania than depression (Popovic et al, 
2012). Psychological interventions appear better to prevent 
depression than mania, with the exception of those with more 
educational components or working through relatives, who may 
be particularly motivated or skilled to prevent mania, rather than 
depression. Interventions based on patient participation or with 
more cognitive and face-to-face participation may be more 
effective preventing depression.  
This study applies Polarity Index, a novel metric developed to 
measure the relative prophylactic efficacy profile of medicaments 
in bipolar disorder, to all available psychological interventions. 
To the best of our knowledge, this is the first attempt to 
determine the efficacy profiles in relapse prevention of 
depressive vs. manic episodes of psychological treatments used 
 
 
as adjuvants to pharmacotherapy in maintenance treatment of 
bipolar disorder.  
According to the results that emerged, cognitive behavioural 
therapy, family-focused therapy and psychoeducation had 
Polarity Index below 1.0, indicating their more antidepressive 
than antimanic prophylactic effects, while caregiver group 
psychoeducation had Polarity Index above 1.0, indicating a 
prevalently antimanic action. Three studies, one cognitive 
behavioural therapy trial (Meyer and Hautzinger, 2011), 
enhanced relapse prevention (Lobban et al., 2010) and brief 
technique-driven interventions (Perry et al.,1999), have Polarity 
Index of 0.89, 1 and 3.36, respectively, but can not be considered 
reliable since the NNT for prevention of any mood episode was 
not statistically significant, and the trials themselves were 
negative. Furthermore, Polarity Index could not be calculated for 
cognitive behavioural therapy by Scott et al. (2006), since not 
only was the NNT for prevention of any episode not significant, 
but NNT for prevention of depressive episodes could not be 
calculated because there was the same number of depressive 
relapses in the intervention group as in the control group. 
Numerous studies did not report relapse rates into mania and 
 
 
depression separately and thus we were unable to calculate their 
Polarity Index (See Table 2). 
Interestingly, in both of the only two of the abovementioned trials 
that presented extended follow-up results (Lam et al.,2003, Lam 
et al.,2005, Colom et al.,2003, Colom et al.,2009) both 
interventions showed a trend in shifting towards PI of 1 over 
time, namely towards a more balanced action. 
The implications of these results are multiple; above all PI may 
guide the clinician into deciding which intervention may be more 
indicated for a single patient. Comparably to pharmacological 
interventions in bipolar disorder, or any kind of intervention in 
medicine for that matter, not all the interventions are equally 
suitable for each patient; thus Polarity Index may represent an 
useful tool to help the clinicians to select the most appropriate 
intervention for each patient in the era of personalized medicine.  
This may be useful in treatment election suggesting that, for 
example, patients with predominant depressive polarity may 
benefit more from cognitive behavioural therapy, family-focused 
therapy or psychoeducation, while caregivers of patients with 
predominant manic polarity may be advised to undertake 
psychoeducation for caregivers. Moreover, combining patient 
 
 
psychotherapy and caregiver-oriented interventions may help 
achieve a more balanced, complementary, Polarity Index.  
This study also evidences paucity of trials assessing long-term 
efficacy of adjunctive psychotherapeutic interventions. Above 
all, it underlines the scarcity of interventions efficacious for 
predominantly manic patients. Interestingly, this is precisely the 
opposite situation as for drugs PI. Most available maintenance 
pharmacotherapies for bipolar disorder have PI above 1, meaning 
that they are better preventing mania than depression (Popovic et 
al, 2012). Psychological interventions appear better to prevent 
depression than mania, with the exception of those with more 
educational components or working through relatives, who may 
be particularly motivated or skilled to prevent mania, rather than 
depression. Interventions based on patient participation or with 
more cognitive and face-to-face participation may be more 
effective preventing depression.  
Polarity Index may guide treatment choice in the context of 
personalized patient care, not only for pharmacological 
treatments but also, and maybe even more so, given the lack of 
any similar tools, for adjunctive psychotherapeutic interventions. 
The fact that the PI of most pharmacotherapies and 
 
 
psychotherapies may be complementary may encourage the 
combination of the two. This metric may help, in the absence of a 
sufficient number of comparative long-term trials, to understand 
the relative efficacy profile of adjunctive psychological 
interventions used in maintenance treatment of bipolar disorder 
and perhaps design interventions with specific profiles. 
The final phase of this study consisted in applying Polarity Index 
to real-world clinical practice.  
  The results of this naturalistic study confirm that, in clinical 
settings, the maintenance treatment of bipolar disorder is in 
accordance with the results emerging from data retrieved from 
randomized clinical trials by calculating NNT for prevention of 
depression vs. mania ratio; namely, patients with MPP presented 
significantly higher Polarity Index, indicating that clinicians 
chose a treatment regimen with stronger antimanic prophylactic 
action, than for DPP patients. The same was true for Polarity 
Index of Atypical Antipsychotics and Polarity Index of Mood 
Stabilizers when analyzed separately. When examining the 
prevalence of prescription of single mood stabilizing drugs, 
lamotrigine was prescribed more frequently in patients with DPP, 
alongside with most antidepressants (TCAs, SSRI and SNRIs) 
 
 
and benzodiazepines. In comparison, Risperidone, Olanzapine 
and Atypical antipsychotics were prescribed more often in the 
MPP group. 
In addition to different pharmacological treatment, several 
clinical differences were detected between the groups. The 
present study confirms most of the findings reported by Colom et 
al. (2006). Main differences, probably due to a larger study 
sample, involved gender, history of psychotic symptoms, 
substance use preceding first episode and seasonal pattern. Other 
findings were consistent, as expected with data from our group 
(Nivoli et al 2011; Undurraga et al, 2011) but also from 
independent samples from other areas, countries, and continents 
(Rosa et al, 2008; Mazzarini et al, 2009;González-Pinto et al, 
2010; Baldessarini et al, 2012). 
In summary, MPP was associated with male gender, younger age, 
younger age at illness onset, younger age of first hospitalization, 
higher hospitalization rate, more manic and hypomanic episodes. 
Regarding clinical features, MPP was associated with Bipolar 
Disorder I primary substance abuse and psychotic symptoms. 
Factors associated with DPP were Bipolar Disorder II, depressive 
onset, more depressive episodes, stressful events preceding 
 
 
illness onset, more suicide attempts and melancholic features. 
These data are mostly in accordance with recently reported 
findings by Baldessarini et al., (2012), who detected that 
Predominant Depression was associated with depressive or mixed 
onset, more mixed-states, and higher suicidal risk and that 
Predominant Mania was associated with initial mania or 
psychosis and more family history. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. LIMITATIONS 
The first limitation of the NNT calculation is that, in order to 
present the most complete data available, we have included both 
RCTs assessing drugs in monotherapy as well as combined with 
mood stabilizers such as lithium and valproate. The studies were 
not completely homogeneous with respect to clinical 
characteristics of the sample (rapid-cycling course, manic/mixed 
states or depression, refractory patients or unbiased samples), 
sample size, and rates of study completion, which may 
compromise to some extent the generalizability of reported 
NNTs. 
Number needed to harm analysis went beyond the scopes of this 
study, although medication selection is based on tolerability as 
well as efficacy. 
 NNTs for the prevention of mixed episodes were omitted since 
most available RCTs have not proceeded to such assessment and 
the number of events in the trials that did look at it was extremely 
small. 
The limitations of Polarity Index are that it has been derived from 
clinical trial data and, therefore, issues related to trial design 
 
 
itself might have influenced the results. These issues include the 
abovementioned adjunctive versus monotherapy design as well as 
the index episode. Recent literature suggests that the polarity of 
the index episode tends to predict the polarity of relapse into a 
subsequent episode in a ratio of about 2:1 to 3:1 and influences 
response to treatment (Calabrese et al., 2004). Thus, a limitation 
of Polarity Index is due to the fact that most maintenance trials, 
from which Polarity Index was calculated, with few exceptions, 
enrolled enriched populations of patients who were currently or 
recently manic or mixed. Missing from most study designs was 
the recruitment of patients with index depressive episodes. 
Exclusion of depressed patients at enrollment may affect the 
polarity of mood episodes during the blinded relapse prevention 
phase since the study design was primarily configured to 
demonstrate efficacy in the delay or prevention of manic 
recurrence. The absence of depressive index episodes in a 
compound whose primary spectrum of efficacy is in depression, 
biases outcome against the drug, or vice versa; which reflects in 
Polarity Index calculation as well. However, the main reason why 
some compounds have only been studied in the context of index 
mania is their failure to separate from placebo in acute bipolar 
 
 
depression trials; hence, the bias against index depression is 
actually caused by the high Polarity Index of the drug, which 
makes it more suitable for the treatment of mania and the 
prevention of subsequent manic episodes, and for this reason we 
believe that the Polarity Index is still fully valid and informative. 
Hence, Polarity Index should be seen as a concept in continuous 
evolution, apace with the ongoing research. Although all the 
available studies published up to date were included, future 
studies might influence Polarity Index values, especially for 
agents assessed in a small number of RCTs. 
Regarding the Polarity Index of psychological interventions the 
main limitation (and strength!) of the Polarity Index is, once 
again,  the fact that it derives from RCT data, meaning that issues 
related to trial design may influence Polarity Index calculations. 
Among these, issues such as a lack of definition of “placebo 
comparator” for psychological interventions and uneven number 
or sessions (or even comparison of an adjunctive intervention to 
“Treatment As Usual” as control comparator), not only between 
different interventions, but also among the experimental and 
control intervention in the same study are evident. The 
medicaments that patients were assuming differ, and were often 
 
 
not specified. Study samples were extremely heterogeneous; 
several trials included patients with Bipolar I or both Bipolar I 
and II diagnosis, euthymic or acute patients. Even the definition 
of “euthymia” (syndromic or symptomic) was not uniform, as 
well as the required duration of euthymia. Differences in 
exclusion criteria, such as the number of previous episodes and 
presence of comorbid pathologies are also common between 
studies. Furthermore the used scales and outcome measures are 
highly heterogeneous. Above all, the name of intervention (e.g. 
cognitive behavioural therapy) does not necessarily mean that 
same treatment protocol was applied; reason why, unlike the 
Polarity Index for drugs, we were unable to pool data when more 
studies were available for one intervention.   
The Polarity Index (of both drugs and psychological 
interventions) does not say anything about the absolute efficacy 
of the intervention, but about the efficacy profile (the higher the 
number, the more biased toward preventing mania as opposed to 
preventing depression). It is a ratio, which does not provide 
information on NNT of an intervention, but rather tells us how 
balanced an intervention is. Both of these concepts, NNT and the 
Polarity Index, need to be considered separately, NNT to 
 
 
determine the efficacy of an intervention, and Polarity Index to 
depict its profile. 
The main limitations of the naturalistic study that was conducted 
include the tertiary-centre nature of the Barcelona Bipolar 
Program at Hospital Clinic, which includes a high percentage of 
difficult-to-treat patients, as well as the abovementioned issues 
regarding Polarity Index metric. Id est, Polarity Index could not 
be calculated for all drugs used in treatment of Bipolar Disorder 
since long-term trials were not conduced for all the agents. In 
some cases, as for Valproate and Oxcarbazepine, Polarity Index 
may not be reliable due to the failure to separate from placebo 
during the pivotal maintenance treatment studies, thus we have 
excluded them from the analysis. Polarity Index was retrieved 
from results of clinical trials, thus issues related to trial design 
itself (adjunctive versus monotherapy design, enrollment of 
enriched populations of patients who were mainly currently or 
recently manic or mixed) may have biased the results as 
previously discussed. An interesting issue is that most 
maintenance trials assessed samples enriched for efficacy; 
however, lamotrigine trials were unique in sense that they 
included study sample enriched for tolerability, and not efficacy, 
 
 
which may have accounted for to the high NNT detected for 
lamotrigine (50.4 for mania prevention and 20.2 for prevention of 
depression) (Popovic et al., 2011; Bowden et al., 2003; Calabrese 
et al., 2003).  Furthermore, one has to bear in mind that the 
calculation of the mean Polarity Index could not reflect the 
pharmacokinetic and pharmacodynamic interactions of drugs in 
combination therapy.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. CONCLUSIONS 
The review of clinical effectiveness of drugs and psychological 
interventions by the means of NNT comparison aimed to 
investigate all the treatments approved as maintenance therapy in 
bipolar disorder. Most of the pharmacological agents assessed 
were effective in the prevention of any kind of mood episode; 
however, different efficacy profiles were found for the prevention 
of manic and/or depressive relapses. The comparison of NNT 
values of the available medicaments may represent a useful 
adjuvant in clinical settings, in order to facilitate implementation 
of long-term pharmacological interventions in patients with 
bipolar disorder.  
Overall, our findings indicate that anticonvulsants, and 
particularly lamotrigine, appear more effective for prevention of 
depressive episodes, while atypical antipsychotics and lithium 
may have a preponderant mania recurrence-preventing action. 
The Polarity Index may be influenced by the capacity of a given 
drug to reduce dopamine outflow in the brain, in the sense that 
the stronger the antidopaminergic action, the higher the Polarity 
Index and the greater the bias toward preventing mania rather 
than depression.  
 
 
Since single drugs have shown differences in efficacy for the 
prevention of one pole over the other, different drugs should be 
prescribed according to the predominance of manic or depressive 
episodes. Since a patient with a predominant depressive polarity 
is much more likely to relapse into a depressive episode, and 
therefore a suitable prophylaxis for that patient might be an agent 
that has been shown to have significant efficacy in preventing 
relapse of depressive episodes, such as lamotrigine. Similarly, a 
patient who has predominant manic polarity might require a 
stronger antimanic prophylactic agent, such as an atypical 
antipsychotic or lithium, in order to prevent further relapse of 
manic episodes. 
When combining drugs, it may be advisable to combine those 
which have different Polarity Index in order to have 
“complementary” efficacy profile, especially in patients who do 
not present a predominant polarity.  
 Polarity Index may guide treatment choice in the context of 
personalized patient care, not only for pharmacological 
treatments but also, and maybe even more so, given the lack of 
any similar tools, for adjunctive psychotherapeutic interventions. 
The fact that the Polarity Index of most pharmacotherapies and 
 
 
psychotherapies may be complementary would encourage   
combinations of the two. This metric may help, in the absence of 
a sufficient number of comparative long-term trials, to 
understand the relative efficacy profile of adjunctive 
psychological interventions used in maintenance treatment of 
bipolar disorder and perhaps design interventions with specific 
profiles. 
Predominant polarity, proposed as a course specifier of particular 
relevance for long-term therapeutic decision-making process and 
outcome predictor (Tohen et al., 2009) in DSM-V (Colom and 
Vieta, 2009), finds its clinical expression in Polarity Index. The 
present study not only provides further evidence to the 
importance of considering patients’ predominant polarity, but 
also examines the actual use of the Polarity Index in routine 
clinical practice. 
The results of the present naturalistic study confirm the 
usefulness of Polarity Index metric in maintenance treatment of 
bipolar disorder. Important clinical differences between 
predominantly manic and predominantly depressed patients 
emerged, and justify the need for differentiated therapeutic 
approach in the two groups. 
 
 
Our study shows that the treatment of patients with MPP was 
oriented mostly towards mania prevention, as evidenced by 
higher Polarity Index, while treatment of DPP patients was 
characterized by lower mean Polarity Index, thus directed 
towards preventing depression. Likewise, the choice of the 
specific drug, even within the same class, varied in accordance 
with patients’ predominant polarity - Second Generation 
Antipsychotics with stronger antimanic vs. antidepressant 
properties were prescribed more often in the Manic Polarity 
group, and vice versa, mood stabilizers with lower Polarity Index 
were prescribed more frequently in Depressive Polarity patients.   
Assuming that specialized care centers may provide higher 
standards of care and better outcomes than non-specilized 
settings (Kessing, in press), the Polarity index may be helpful as 
a tool to assess the quality of maintenance prescription for 
bipolar patients; hence, if MPP patients receive higher PI 
regimens than DPP patients, the treatment is likely to be evidence 
based. 
 
 
 
 
 
8. FUTURE DIRECTIONS 
The results of the study suggest that the use of Polarity Index 
might lead to an individualized optimization in the treatment of 
bipolar patients. In order to replicate the findings, further studies 
applying Polarity Index to the pharmacological and/or 
psychological treatment of bipolar patients are required. At the 
moment, Polarity Index metric is being validated in Porto Alegre, 
Brazil and Thessaloniki, Greece.  
A possible evolution of my work consists in correlating 
antidepressive vs. antimanic dosages of each drug, calculated 
from all the available clinical trials, with the Polarity Index, in 
attempt to predict the most effective treatment for each individual 
patient. This could be one of the first steps in the creation of 
“precision psychiatry”, with an important impact above all on 
therapeutic management of patients with bipolar disorder, but 
could also carry a secondary benefit of being able to direct the 
choice of dosages and focus on specific sub populations of 
bipolar patients that would be most likely to respond to a certain 
drug and thus could be of interest also for clinical trials.  
 
 
 
Successful long-term management often appears to require 
combination treatment, and although assessing combined 
treatments went beyond the aims of our study, lack of such trials, 
e.g., lamotrigine as add-on treatment, should be an object of 
future research.  Randomized clinical trials for maintenance 
treatment of Bipolar Disorder are not only scarce; they are 
completely lacking for various agents. Carbamazepine is a clear 
example; although it was the first agent after lithium to be 
advocated for long-term treatment of bipolar disorder and 2 
lithium controlled studies indicate drug's efficacy in relapse 
prevention (Greil et al., 1997; Hartong et al., 2003), by the time 
the research was conducted there were no available long term 
placebo-controlled trials and thus Polarity Index of 
carbamazepine, could not be calculated. Future research needs to 
address the long-term effectiveness and the Polarity Index of 
agents such as carbamazepine, oxcarbazepine, valproate and 
newer antipsychotics such as paliperidone or asenapine. 
As to the psychological interventions, future studies are needed 
in order to isolate the “active ingredients” responsible for 
therapeutic response and thus enable to design new, eventually 
 
 
shorter, interventions that would focus on the essential 
components in order to prevent episodes of different polarity. 
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10.) TABLES AND FIGURES 
 
Table 1. Characteristics of randomized controlled trials included in NNT 
analyses for Recurrence Prevention of Pharmacological Agents used for 
Maintenance Treatment of Bipolar Disorder  
Trial  Inclusion 
criteria          
(maintenance 
phase) 
Duration 
(weeks) 
Number 
randomized 
 Dosage 
(mg/day) or 
plasma levels /  
Mean dosage 
Bowden  et 
al., 2000 
Bipolar I  
18-70 years 
Manic episode 
≤3 months 
before 
randomization. 
MRS ≤11 
 DSS ≤13 
GAS > 60,  
No serious 
suicidal risk 
 
52 VPA: 187 
LI: 90 
PLA:92 
VPA: 71-125 
μg/mL 
LI: 0.8-1.2 
mmol/L 
Bowden  et 
al., 2003 
Bipolar I   
≥ 18 years 
Current or 
recent  
(hypo)mania 
≥1 additional 
(hypo)manic 
and 1 
depressive 
episode in the 
past 3 years 
76 LAM: 59 
LI: 46 
PLA:70 
LAM: 100-
400mg/die 
LI: 0.8-1.1 
mEq/L 
Bowden  et 
al., 2010 
Bipolar I   
≥ 18 years 
Curent or recent 
manic/ mixed 
episode  
MRS≥14 
 
24 ZIP+LI/VPA= 
127 
PLA+LI/VPA= 
113 
ZIP: 80-160 
mg/die 
LI: 0.6–1.2 
mEq/L  
 Mean:  0.7-0.9 
mEq/L   
VPA:50-125 
μg/mL    
Mean: 67.4-72.8  
Calabrese Bipolar I and II 26  LAM: 90 LAM: 100–300 
 
 
et al., 2000 Rapid cycling 
≥ 18 years 
≤14 HAM-D 
 ≤12 MRS 
 < 3 on item 3 
HAM-D 
stable for 4 
weeks 
 
PLA: 87 mg/day 
 
Calabrese 
et al., 2003 
Bipolar I   
≥ 18 years 
Current or 
recent MDE 
≥1 additional 
(hypo)manic 
and 1 
depressive 
episode in the 
past 3 years 
72 LAM: 221 
LI: 121 
PLA:121 
LAM:50-
400mg/die  
Mean:200mg/die 
LI: 0.8-1.1 
mEq/L 
Mean: 0.8±0.3 
mEq/L 
Keck  et 
al., 2007 
Bipolar I   
≥ 18 years 
YMRS≤ 10 
MADRS≤ 13 
 No 
hospitalization 
in previous 3 
months 
100 
   
ARI=78 
PLA=83 
ARI: 15-
30mg/day   
Mean: 23.8 
mg/day   
Macfadden  
et al., 2009 
Bipolar I   
18-70 years 
≥4 episodes in 
the past year 
52 RLAI+ TAU= 
65 
PLA+ TAU= 
59 
RLAT: 25-50mg 
/ 2 weeks 
Prien et al., 
1973 
Manic-
depressive, 
manic type 
24 LI:101 
PLA: 104 
  
LI: 0.5-1.4 
mEq/L 
 
Quiroz  et 
al., 2010 
Bipolar I   
 18-65 years 
 Recent 
manic/mixed 
episode or  
stable patients 
with   ≥1 mood 
episode in past 
4 months 
  
96 RLAI=140 
PLA= 136 
RIS: 12.5-50 mg 
i.m. Mean:25mg 
Suppes  et 
al., 2009 
Bipolar I   
≥ 18 years 
YMRS≤ 10 
MADRS≤ 13 
104 QUE+LI/VPA= 
310 
PLA+LI/VPA= 
313 
QUE: 400–
800mg/day 
Mean: 519 
mg/die 
 
 
LI: 0.5–1.2 
mEq/L  
 Mean: 0.71-0.74 
mEq/L   
VPA:50-125 
μg/mL    
Mean:  68.91-
71.38 μg/mL    
Tohen  et 
al., 2006 
Bipolar I 
≥ 18 years 
YMRS≤ 12 
HAM-D≤ 8 
2 prior mixed or 
manic episodes 
in past 6 years 
 
48 OLZ=225 
PLA= 136 
 OLZ:  5–20 
mg/day 
Tohen et 
al., 2004 
Bipolar I 
18-70 years 
YMRS≤ 12 
HRSD-21≤ 8 
 
72 LI/VPA+PLA= 
48   
LI/VPA+OLZ= 
51   
OLZ:5-20 
mg/day  
Mean: 12.5 
mg/day 
LI: 0.66-0.86 
mEq/l 
VPA: 60.1-73.8  
μg/mL    
Vieta  et 
al., 
2008(b) 
Bipolar I or II 
≥ 18 years 
YMRS≤ 12 
MADRS≤20 
No acute phases 
in 6 months 
 
52 OXC+LI=26 
PLA+LI=29 
OXC: 1200 
mg/day   
LI:0.6 mEq/l 
 
Vieta et 
al., 2008 
(a) 
Bipolar I 
≥ 18 years 
YMRS≤ 12 
HAM-D≤ 12 
 
104 
   
QUE+LI/VPA= 
336 
PLA+LI/VPA= 
367 
QUE: 400 -800 
mg/day Mean: 
497 mg/day 
LI: 0.5–1.2 
mEq/L   
VPA:50-125 
μg/mL    
 
 
 
 NNT analyses refer to 12 month- period.  Trials are in alphabetic order. 
PLA=placebo, ARI= aripiprazole, OLZ= olanzapine, LI=lithium, VPA= valproate, 
QUE=quetiapine, RLAI= risperidone long acting injection, TAU= treatment as usual, 
ZIP=ziprasidone, LAM=lamotrigine, OXC= oxcarbazepine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weisler et 
al., 2008 
Bipolar I    
YMRS ≤12 
 MADRS ≤12   
Acute current or 
recent (past 26 
weeks) manic, 
depressive, or 
mixed index 
episode treated 
with QUE 
104  QUE= 404 
LI= 364 
PLA= 404 
QUE: 300-800 
mg/day 
 Li: 0.6-1.2 
mEq/L 
 
 
Table 2. Relapse rates reported in Randomized Controlled Trials of 
Pharmacological Agents used for Maintenance Treatment of Bipolar Disorder  
  
 
Any episode        
n (%) 
Mania             
n (%) 
Depression         
n (%) 
 
PCB 
relapse 
Drug 
relapse 
PCB 
relapse 
Drug 
relapse 
Placebo 
relapse 
Drug 
relapse 
Aripiprazole 
(Keck et al., 
2007) 
43/83 
(51.81) 
25/77 
(32.47) 
23/83 
(27.71) 
9/77 
(11.69) 
13/83 
(15 .66) 
11/77 
(14.28) 
Olanzapine 
(Tohen et 
al., 2006) 
109/136 
(80.14) 
105/225 
(46.66) 
44/136 
(32.35) 
27/225 
(12) 
53/136 
(38.97) 
68/225 
(30.22) 
Olanzapine 
+ LI/VPA 
(Tohen et 
al., 2004)* 
21/38 
(55.26) 
11/30 
(36.66) 
11/38 
(28.94) 
6/30 
(20) 
15/38 
(39.47) 
7/30 
(23.33) 
Quetiapine 
+ LI/VPA 
(Vieta et al., 
2008) 
180/367 
(49.04) 
62/336 
(18.53) 
96/367 
(26.16) 
36/336 
(10.71) 
84/367 
(22.89) 
26/336 
(7.74) 
Quetiapine  
+ LI/VPA 
(Suppes et 
al., 2009) 
163/313 
(52.08) 
63/310 
(20.32) 
61/313 
(19.49) 
22/310 
(19.49) 
102/313 
(32.59) 
41/310 
(13.23) 
Quetiapine 
(Weisler, 
2009) 
343/404 
(84.90) 
162/404 
(40.10) 
291/404 
(72.03) 
121/404 
(29.95) 
186/404 
(46.04) 
65/404 
(16.09) 
Risperidone 
LAI (Quiroz 
et al., 2010) 
76/135 
(56.29) 
42/140 
(30) 
62/135 
(45.93) 
22/140 
(15.71) 
41/135 
(10.37) 
14/135 
(14.29) 
Risperidone
LAI +TAU 
(Macfadden 
et al., 2009) 
27/59 
(45.76) 
15/65 
(23.08) 
12/59 
(20.34) 
5/65 
(7.69) 
11/59 
(18.64) 
8/65 
(12.31) 
Ziprasidone 
+ LI/VPA 
(Bowden et 
al., 2010) 
36/111 
(32.43) 
25/127 
(19.69) 
14/111 
(12.61) 
7/127 
(5.51) 
16/111 
(14.41) 
16/127 
(12.60) 
Lamotrigine
(Bowden et 
al., 2003) 
49/70 
(70) 
28/59 
(47.46) 
22/70 
(31.43) 
16/59 
(27.12) 
21/70 
(30) 
8/59 
(13.56) 
Lamotrigine
(Calabrese 
et al.,2003) 
66/119 
(55.46) 
115/215 
(53.49) 
19/119 
(15.97) 
38/215 
(17.67) 
47/119 
(39.50) 
77/215 
(35.81) 
 
 
Lamotrigine
(Calabrese 
et al., 2000) 
64/87 
(73.56) 
53/90 
(58.89) 
N.A. N.A. N.A. N.A. 
Lamotrigine
(Goodwin et 
al., 2004) 
115/191 
(60.21) 
143/280 
(51.07) 
47/191 
(24.61) 
58/280 
(20.71) 
68/191 
(35.60) 
85/280 
(30.36) 
Lithium 
(Prien et al., 
1973) 
71/104 
(68.27) 
36/101 
(35.64) 
53/104 
(50.96) 
23/101 
(22.77) 
14/104 
(13.46) 
9/101 
(8.91) 
Lithium 
(Goodwin et 
al., 2004) 
115/191 
(60.21) 
74/167 
(44.31) 
47/191 
(24.61) 
18/167 
(10.78) 
68/191 
(35.60) 
56/167 
(33.53) 
Lithium 
(Bowden et 
al.,2003) 
49/70 
(70) 
18/46 
(39.13) 
22/70 
(31.43) 
6/46 
(13.04) 
21/70 
(30) 
10/46 
(21.74) 
Lithium 
(Calabrese 
et al., 2003) 
66/119 
(55.16) 
56/120 
(46.67) 
19/119 
(15.97) 
10/120 
(8.93) 
47/119 
(33.50) 
46/120 
(38.33) 
Lithium 
(Bowden et 
al., 2000) 
36/94 
(38.30) 
28/91 
(30.77) 
21/94 
(22.34) 
19/91 
(20.80) 
15/94 
(9.89) 
9/91 
(15.96) 
Lithium 
(Weisler et 
al., 2009) 
343/404 
(84.90) 
149/364 
(40.93) 
291/404 
(72.03) 
102/364 
(28.02) 
186/404 
(46.04) 
66/364 
(18.13) 
Valproate 
(Bowden et 
al., 2000) 
36/94 
(38.29) 
45/187 
(24.06) 
21/94 
(22.34) 
33/187 
(17.65) 
15/94 
(15.96) 
12/187 
(6.42) 
Oxcarbazepi
ne +LI  
(Vieta et al., 
2008) 
17/29 
(58.62) 
10/26 
(38.46) 
8/29 
(27.58) 
4/26  
(15.38) 
9/29 
(31.03) 
3/26 
(11.54) 
 
TAU= Treatment as usual; LI=Lithium; VPA=Valproate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Number needed to treat (NNT) values for Recurrence Prevention of 
Pharmacological Agents used for Maintenance Treatment of Bipolar Disorder  
 
 
 NNT  
Any episode 
95% CI   
NNT  
Mania 
95% CI   
NNT 
Depression 
95% CI   
Aripiprazole 
(Keck et al., 2007) 
6 
 [2.9-23]    
7 
 [3.6, 24.9]    
 50.0 
[7.7, Infinity] 
Olanzapine  
(Tohen et al., 2006) 
3 
[2.3, 4.2] 
5 
[3.4, 8.8] 
12 
[5.3, Infinity] 
Olanzapine + 
Lithium/Divalproex 
(Tohen et al., 2004)* 
6 
[2.4, Infinity] 
12 
[3.4, Infinity] 
 
6 
[2.6, Infinity] 
Quetiapine + 
Lithium/Divalproex 
(Vieta et al., 2008) 
4 
[2.7-4.2] 
7  
[4.8,10.1] 
7 
[4.9, 10.0] 
Quetiapine + 
Lithium/Divalproex 
(Suppes et al., 2009) 
4 
[2.6, 4.1] 
9  
[5.7, 14.0] 
6 
[3.9, 7.7] 
Quetiapine  
(Weisler et al., 2009) 
3 
[2, 2.6 ] 
3 
[2, 2.8] 
4 
[2.8, 4.2] 
Risperidone LAI  
(Quiroz et al., 2010) 
4 
[2.4, 5.6] 
4 
[2.5, 5.0] 
26 
[8.6, Infinity] 
Risperidone LAI +  
Treatment as Usual 
(Macfadden et al., 
2009) 
5  
[2.6, 15.7] 
 8 
[4.0, 198.7] 
16 
[5.2, Infinity] 
Ziprasidone + 
Lithium/Divalproex 
 (Bowden et al., 
2010)   
8  
[4.2, 61.5] 
 
15 
[6.9,Infinity] 
56 
[9.5, Infinity] 
Lamotrigine  5   24 7 
 
 
(Bowden et al., 2003) [2.6, 17.0] [5.0, Infinity] [3.3, 38.5] 
Lamotrigine       
(Calabrese et 
al.,2003)  
 51 
[7.6, Infinity] 
59 
[10.0, Infinity] 
 28 
[6.9, Infinity] 
Lamotrigine  
(Calabrese et 
al.,2000) 
7 
[3.5, 108.8] 
N.A N.A. 
Lamotrigine 
(Goodwin et al., 
2004) 
 11 
[5.5, 1764.7] 
 26 
[8.6, Infinity] 
 20 
[7.2, Infinity] 
Lithium  
(Prien et al., 1973) 
4 
[2.2, 5.1] 
4 
[2.5, 6.4] 
22 
[7.6, Infinity] 
Lithium 
 (Goodwin et al., 
2004) 
 7 
[3.8, 17.7] 
 8 
[4.6, 16.3] 
 49 
[8.4, Infinity] 
Lithium  
(Bowden et al.,2003) 
4 
[2.3, 20.5] 
 6 
[3, 26.4] 
13 
[4.1, Infinity] 
Lithium 
(Calabrese et al., 
2003) 
12 
[4.7, Infinity] 
14 
[6.3, Infinity] 
86 
[7.4, Infinity] 
Lithium  
(Bowden et al., 2000)  
14 
[4.7, Infinity] 
69  
[7.5, Infinity] 
17 
[6.4, Infinity] 
Lithium 
 (Weisler et al., 2009) 
3   
[2, 2.6 
3 
[2.2, 2.7] 
4 
[2.8, 4.4] 
Valproate  
(Bowden et al., 2000) 
 7 
 [3.9, 37.7] 
22 
[6.8, Infinity] 
11 
[5.6, 74.3]  
Oxcarbazepine + 
Lithium 
 (Vieta et al., 2008) 
5 
[2.2, Infinity] 
9 
[3.0, Infinity] 
6 
[2.5, Infinity] 
 
* Data referring to symptomatic relapse. CI= Confidence Interval, LAI= Long Acting 
Injection. Note: Significant NNTs are in bold letters 
 
 
 
Table 4.  Characteristics and relapse rates of the included trials for adjunctive 
Psychotherapies in Maintenance treatment of Bipolar Disorder 
Trial characteristics Study Results 
Manic Relapse Depressive 
Relapse 
Interven
tion 
Control 
 
Inclusion 
criteria           
(maintenanc
e phase) 
Trial 
Characteri
-stics Control 
Group 
Exper. 
Group  
Control 
Group 
Exper.
Group  
BTDI 
(Perry et 
al., 
1999) 
 
Routine 
care 
BD I or II 
≥2 relapses, 
1 in the 
previous year 
Age: 18-75 
No primary 
substance 
abuse 
7-12 
sessions 
11/35 
31.43% 
2/33 
6% 
9/35 
25.71% 
11/33 
33.33% 
CGPE 
(Reinare
s et al., 
2008) 
Meetings 
without 
interventi
on 
Caregivers of 
BD I or II 
patients, 
Age: 18-60 
euthymia ≥3 
months, on 
pharmacolog
ical 
treatment for 
BD 
12 weeks of 
intervention 
and 1 year 
follow-up 
21/56 
37.5% 
10/57 
17.54% 
23/56 
41.07% 
17/57 
29.82% 
CBT 
(Lam et 
al., 
2003) 
 
TAU  BD I 
Pharmacolog
ical 
treatment 
Age: 18-70 
years 
≥2 episodes 
in past 2 
years or 3 
episodes in 
past 5 years 
Current 
euthymia; 
BDI<30, 
MRS<9 
No substance 
use 
disorders, not 
suicidal 
14 sessions 
in first 6 
months + 2 
booster 
sessions in 
second 6 
months, 
performed 
by 
psychologis
ts 
16/48 
33.33% 
21/48 
43.75% 
10/48 
20.83% 
25/48 
52.08% 
CBT 
(Lam, 
2005) 
TAU BD I 
≥2 episodes 
in past 2 
years/ 3 
30 months 
CBT+ 
medication 
vs. 
31/46 
67% 
23/46 
50% 
17/44 
38% 
32/48 
66% 
 
 
episodes in 5 
years prior to 
recruitment.  
Not actively 
suicidal, no 
substance 
use disorder 
medication 
only 
12–18 
individual 
sessions 
in 6 months  
CBT 
(Meyer 
and 
Hautzing
er, 2011) 
Supportiv
e 
treatment 
 BD I or II 
Age: 18-65   
Assuming 
medication 
No: primary 
diagnosis of 
non-affective 
disorder, 
current 
affective 
episode, 
substance-
induced 
affective 
disorder or 
affective 
disorder due 
to a general 
medical 
condition, no 
current 
substance 
dependency,  
no cognitive 
impairment, 
no current 
psychologica
l treatment.   
20 sessions 
of CBT or 
Supportive 
Therapy 
over 9 
months.  
Follow up: 
24 months.  
 
  
8/38 
21.05% 
 10/38 
26.32% 
 14/38 
36.84% 
 7/38 
18.42% 
CBT 
(Scott et 
al., 
2006) 
TAU BD I or II 
Age ≥18 
years  
≥2 acute 
episodes,1in 
previous 
year; contact 
with mental 
health 
services   
No: rapid-
cycling, BD 
secondary to 
an organic 
cause, 
severe 
borderline 
72 weeks 
20  weekly 
sessions of 
CBT   until 
week 15 
and then 
with 
gradually 
reducing 
frequency 
until week 
26 + 2 
‘booster 
sessions’   
25/126 
19% 
28/127 
22% 
 
39/126 
30% 
39/127 
30% 
 
 
PD,  suicidal 
ideation/ 
intent in past 
3 months 
continuous 
substance 
misuse, 
current 
mania, 
current 
systematic 
psychologica
l treatment  
ERP 
(Lobban 
et al., 
2010) 
TAU BD I or II 
≥2 relapses, 
1 in the past 
12 months or 
2 in past 3 
years 
Euthymic 
≥4wks 
No rapid 
cycling, 
primary 
substance 
abuse or 
organic 
cause 
6 x 1h 
sessions 
Care 
coordinator
s (trained 
by a nurse)  
8/40 
20% 
9/40 
22.5% 
16/40 
40% 
17/40 
42.5% 
FFT 
(Miklow
itz, 
2003) 
Crisis 
managem
e-nt 
interventi
on and 
TAU 
BD I or II. 
Acute 
episode in 
the past 3 
months 
Aged 18-65 
years 
No 
development
al disability 
or neurologic 
disorder 
 No 
substance 
use disorders 
in the 
previous 6 
months 
Regular 
contact with 
a caregiver 
English 
speaking 
 2 years 
Prior 
episodes 
7.9±17.9 
(FFT) 
5.7±13.4 
(CM) 
FFT: 21 
sessions   
CM:  2 
sessions  
Duration: 9 
months. 
Pharmacoth
erapy for 2 
study years. 
6/70 
8% 
 
5/31 
16% 
 
26/70 
37% 
6/31 
19% 
PE Meetings BD I or II 20 x 90- 20/60 12/60 19/60 8/60 
 
 
 
BD= Bipolar Disorder; BTDI= Brief Technique-Driven Intervention; PE= Psychoeducation; 
CGPE=Caregiver Group Psychoeducation; CBT= Cognitive Behavioural Therapy; TAU= 
Treatment as usual; ERP= Enhanced Relapse Prevention; FFT= Family Focused Therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Colom 
et al., 
2003) 
without 
interventi
on 
Age: 18-65 
years 
6 months of 
euthymia 
(YMRS <6; 
HDRS-17 
<8) 
No substance 
abuse, no 
mental 
retardation or 
organic brain 
damage, no 
deafness 
minute 
sessions + 
2yrs follow 
up  
33.33% 20% 31.67% 13.33% 
PE 
(Colom 
et al., 
2009) 
Meetings 
without 
interventi
on 
Note: 5-year 
follow up of 
the Sample 
in Colom et 
al.,2003 
BD I or II 
Age: 18-65 
years 
6 months of 
euthymia 
(YMRS <6; 
HDRS-17 
<8) 
No substance 
abuse, no 
mental 
retardation or 
organic brain 
damage, no 
deafness 
20x90-
minute 
sessions + 
2yrs follow 
up  
48/60 
80% 
32/60 
53.33% 
50/60 
83.33% 
29/60 
48.33% 
 
 
Table 5. Excluded trials and reasons for their exclusion 
 
 
Trial  Reason for exclusion  
Ball, 2006 Depression and mania relapse rates not reported  
Castle, 2010 Depression and mania relapse rates not reported  
Clarkin, 1998 Depression and mania relapse rates not reported  
Cochran, 1984 Relapse rate not assessed ; Small sample size  
D’Souza   Depression and mania relapse rates not reported 
Frank, 2005  Relapse rates not reported 
Gomes 2011  Depression and mania relapse rates not reported 
González-Isasi 2010  Small sample size 
Johnson, 2009 Small sample size; Absence of a control group 
Kessing 2011 Sample composed of bipolar and depressed patients; 
Relapse rates not published   
Miklowitz 2008  Adolescents Depression and mania relapse rates not 
reported 
Miklowitz, 2007  Depression and mania relapse rates not reported 
Miller 2008  Depression and mania relapse rates not reported 
Miller, 2004 Assessed only time to recovery, not recurrence of mood 
episodes     
Perlick 2010 Depression and mania relapse rates not reported 
Rea 2003  Absence of a control group   
Simon 2006 Relapse rates not clearly reported 
Solomon 2008 Small sample size  
Van Gent, 1991 Small sample size 
Weiss 
2000,2007,2009 
Depression and mania relapse rates not reported 
Williams 2008 Depression and mania relapse rates not reported 
Zaretsky 2008 Absence of a control group, Depression and mania 
relapse rates not reported 
 
 
Table 6 . NNT for prevention of mania, depression, and any mood episode and 
Polarity Index of each study.  
 
 
NNT= Number Needed to Treat, BD= Bipolar Disorder 
 
 
 
 
 NNT  
Mania
NNT 
Depression
NNT  
Any 
episode  
Polarity 
Index 
Brief technique-driven 
interventions (Perry et al., 1999) 
3.9 13.1 11.3 3.36 
Enhanced relapse prevention for 
BD (Lobban et al., 2010) 
40 40 20 1 
Cognitive behavioural therapy  
(Lam et al., 2003) 
9.6  3.2 4.8  0.33 
Psychoeducation  
(Colom et al., 2003) 
7.5 5.5 4.6 0.73 
Caregiver group psychoeducation 
(Reinares et al., 2008) 
5.0 8.9 4.2 1.78 
Family-focused therapy 
(Miklowitz et al., 2003) 
13.2 5.6 5.3 0.42  
Cognitive behavioural therapy 
(Lam et al., 2005) 
5.7 3.6 4.9 0.63 
Cognitive behavioural therapy 
(Meyer and Hautzinger, 2011) 
19 5.4 4.8 0.89 
Psychoeducation  
(Colom et al., 2009) 
7.5 3.7 2.9 0.78 
 
 
Table 7. Demographic and clinical characteristics of the study sample   
 
 
 Manic 
Polarity 
n (%) 
Depressive 
Polarity  
n (%) 
χ² p 
Gender   11.591 0.001*
    Male 69/114 (60.53) 56/143 (39.16)   
Level of working 
activity 
  1.844  0.175 
    Good 74/110 (67.27) 77/131 (58.78)   
Authonomy   2.179 0.140 
    Good 95/109 (87.16) 104/130(80.00)   
Educationallevel   0.601 0.438 
    Qualified 50/111 (45.05)    68/136 (50.00)   
Subtype   23.530 0.000*
    BD I   100/113(88.50) 86/140 (61.43)   
    BD II 13/113(11.50) 54/140 (38.57)   
First episode   76.365 0.000*
    Depression 39/110(35.45) 119/134 (88.81)   
Primary    Substance use     17.174 0.001*
    Yes 68/102 (66.67) 61/128 (47.65)   
Primary Life events    6.915 0.009*
    Yes  49/92 (53.26)  85/120 (70.83)   
Substance use   27.853 0.366 
    None  27/108 (25) 48/136 (35.29)   
    Alcohol 31/108 (28.70) 36/136 (26.48)   
    Cannabinoids 29/108 (26.85) 53/136 (38.97)   
Rapidcycling   0.000 0.992 
    Yes 12/106(11.32) 15/132(11.36)   
Melancholia   11.281 0.001*
    Yes 23/100 (23.0) 54/121 (44.63)   
 
 
Catatonia   0.001 0.973 
    Yes 4/99 (4.04) 5/121 (4.13)   
Seasonal pattern   2.251 0.134 
    Yes 21/102(20.59) 38/130 (29.23)   
Psychotic symptoms   8.699 0.003*
    Yes 75/109(68.81) 66/132(50.0)    
Psychosis at I episode   14.915 0.000*
    Yes  55/90 (61.11)  35/90 (38.88)   
Suicidal Ideation   2.467 0.116 
    Yes 52/92 (56.52) 85/127 (66.93)   
Suicide Attempts   4.319 0.038*
    Yes 22/100 (22.0) 43/124 (34.68)   
Family History of 
Affective Disorders 
  0.911 0.340 
    Yes 64/106(60.38)  85/128 (66.41)   
Family History of 
Suicide 
  1.811 0.178 
    Yes 12/107(11.21) 22/126 (17.46)   
Family History of 
Psychiatric Disorders 
  0.091 0.763 
    Yes 86/108(79.62) 103/132 (78.03)   
Atypical depression   2.530 0.112 
    Yes 13/94 (13.83) 26/116 (22.41)   
Medical Comorbidity    0.702 0.402 
    Yes 18/41 (43.90) 21/59 (35.59)   
Psychoeducation   3.229 0.199 
    Yes 17/103(16.50)   14/127 (11.02)   
Compliance   0.165 0.684 
    Good 71/105(67.62) 82/126 (65.08)   
Axis I comorbidity   20.877 0.589 
    Yes 27/105(25.71) 37/131 (28.24)   
Axis II comorbidity   20.647 0.192 
 
 
    Yes 18/105(17.14) 32/132 (24.24)   
Axis III comorbidity   3.543 0.315 
    Yes 45/97 (46.39) 49/114 (42.98)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8. Differential Quantitative Features between Manic Polarity and 
Depressive Polarity Groups 
 
 
 Manic 
Polarity 
(n=114) 
Mean (SD) 
Depressive 
Polarity 
(n= 143) 
Mean (SD) 
 t/ U p 
Age 47.29(14.50) 57.00(27.85) -3.375 0.001* 
Age of onset 26.16 (10.70) 30.57(11.82) -3.009 0.003* 
Age of firsthospitalization 29.89 (13.56) 37.35(14.185) -3.268 0.001* 
Number of hospitalizations 2.17 (2.566) 1.40 (1.78) 2.648 0.009* 
Total number of episodes 11.67(18.23) 12.21 (16.40) -0.245 0.807 
Number of manicepisodes 3.79 (4.65) 0.98 (1.33) 6.202 0.000* 
Number of hypomanic 
episodes 
4.79 (9.94) 2.35 (4.50) 2.336 0.021* 
Number of depressive 
episodes 
2.86 (5.86) 8.20 (11.66) -4.755 0.000* 
Number of mixed episodes 0.45 (1.54) 0.73 (1.61) -1.360 0.175 
Number of suicide attempts 0.80 (3.841) 0.75 (1.366) 109.908 0.129 
 
 
 
 
 
 
 
 
 
 
 
Table 9. Polarity Index of drugs in Manic and Depressive Polarity groups 
 
 Manic 
Polarity  
(n=114) 
Depressive 
Polarity 
(n= 143) 
 
 Mean SD Mean SD p Mann-
Whitney 
U  
p Kolmogorov-
Smirnov Z 
p 
Polarity 
Index 
AP+MS  
3.68 
 
3.19 
 
2.22 2.36 0.001* 3385.5 0,000* 2.069 0.000*
Polarity 
Index 
AP 
6.78   4.68 4.77 4.53 0.044* 1281.5 0.006* 1.425 0.035*
Polarity 
Index 
MS 
1.31    0.23 
 
1.14 0.38 0.001* 2679.0 0.001*  1.429 0.034*
 
 
AP= Antipsychotics, MS= Mood Stabilizers; SD= Standard Deviation 
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Figure 1. Second Generation Antipsychotics in Maintenance Treatment of 
Bipolar Disorder (significant NNTs)
Any episode Mania Depression
 
 
 
SGA= second generation antipsychotic, MS= mood stabilizer, PLA=placebo, ARI= 
aripiprazole, OLZ= olanzapine, LI=lithium, VPA= valproate, QUE=quetiapine, RLAI= 
risperidone long acting injection, TAU= treatment as usual, ZIP=ziprasidone 
 
 
 
 
 
 
 
 
Figure 2. Logarithmic distribution of Polarity Index for the assessed 
interventions 
 
 
 
 
 
PI= Polarity Index, CBT= cognitive behavioural therapy, FFT= family-focused 
therapy, PE= psychoeducation 1Lam et al., 2003; 2Lam et al., 2005; 3Miklowitz 2003;  
, 2011; 4Colom et al.,2003; 5Colom et al., 2009;; 7Reinares 2008  
 
 
 
 
 
 
 
